Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 609428, 71 pages
http://dx.doi.org/10.1155/2015/609428
Review Article

Monoamine Reuptake Inhibitors in Parkinson’s Disease

1Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
3Department of Pharmacology and Division of Neurology, Faculty of Medicine, Université de Montréal and Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada

Received 19 September 2014; Accepted 26 December 2014

Academic Editor: Maral M. Mouradian

Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Hornykiewicz and S. J. Kish, “Biochemical pathophysiology of Parkinson's disease,” Advances in Neurology, vol. 45, pp. 19–34, 1987. View at Google Scholar · View at Scopus
  2. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger, “Brain dopamine and the syndromes of Parkinson and Huntington clinical, morphological and neurochemical correlations,” Journal of the Neurological Sciences, vol. 20, no. 4, pp. 415–455, 1973. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Ehringer and O. Hornykiewicz, “Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system,” Klinische Wochenschrift, vol. 38, pp. 1236–1239, 1960. View at Google Scholar
  4. S. Fahn, L. R. Libsch, and R. W. Cutler, “Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor,” Journal of the Neurological Sciences, vol. 14, no. 4, pp. 427–455, 1971. View at Publisher · View at Google Scholar · View at Scopus
  5. J. G. Greenfield and F. D. Bosanquet, “The brain-stem lesions in Parkinsonism,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 16, pp. 213–226, 1953. View at Google Scholar
  6. C. D. Marsden, “The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture,” Neurology, vol. 32, no. 5, pp. 514–539, 1982. View at Publisher · View at Google Scholar · View at Scopus
  7. P. L. McGeer and E. G. McGeer, “Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea,” Journal of Neurochemistry, vol. 26, no. 1, pp. 65–76, 1976. View at Google Scholar · View at Scopus
  8. P. L. McGeer, E. G. McGeer, and H. C. Fibiger, “Glutamic-acid decarboxylase and choline acetylase in Huntington's chorea and Parkinson's disease,” The Lancet, vol. 2, no. 7829, pp. 622–623, 1973. View at Google Scholar · View at Scopus
  9. R. Nandhagopal, L. Kuramoto, M. Schulzer et al., “Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study,” Brain, vol. 132, no. 11, pp. 2970–2979, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Scatton, F. Javoy-Agid, L. Rouquier, B. Dubois, and Y. Agid, “Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease,” Brain Research, vol. 275, no. 2, pp. 321–328, 1983. View at Publisher · View at Google Scholar · View at Scopus
  11. G. M. Halliday, P. C. Blumbergs, R. G. H. Cotton, W. W. Blessing, and L. B. Geffen, “Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease,” Brain Research, vol. 510, no. 1, pp. 104–107, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Kerenyi, G. A. Ricaurte, D. J. Schretlen et al., “Positron emission tomography of striatal serotonin transporters in Parkinson disease,” Archives of Neurology, vol. 60, no. 9, pp. 1223–1229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Kish, J. Tong, O. Hornykiewicz et al., “Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease,” Brain, vol. 131, no. 1, pp. 120–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. D'Amato, R. M. Zweig, P. J. Whitehouse et al., “Aminergic systems in Alzheimer's disease and Parkinson's disease,” Annals of Neurology, vol. 22, no. 2, pp. 229–236, 1987. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Chan-Palay and E. Asan, “Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression,” Journal of Comparative Neurology, vol. 287, no. 3, pp. 373–392, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Fahn, “The history of dopamine and levodopa in the treatment of Parkinson's disease,” Movement Disorders, vol. 23, supplement 3, pp. S497–S508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Hornykiewicz, “L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent,” Amino Acids, vol. 23, no. 1–3, pp. 65–70, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Hely, J. G. L. Morris, W. G. J. Reid, and R. Trafficante, “Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years,” Movement Disorders, vol. 20, no. 2, pp. 190–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. Parkinson Study Group CALM Cohort Investigators, “Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease,” Archives of Neurology, vol. 66, no. 5, pp. 563–570, 2009. View at Publisher · View at Google Scholar
  20. T. Kenakin, “Receptor theory,” in Current Protocols in Pharmacology, S. J. Enna and M. Williams, Eds., pp. 221–227, John Wiley & Sons, Hoboken, NJ, USA, 1998. View at Google Scholar
  21. T. Kenakin, “Principles: receptor theory in pharmacology,” Trends in Pharmacological Sciences, vol. 25, no. 4, pp. 186–192, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kenakin, “Receptor theory,” Current Protocols in Pharmacology, chapter 1: unit 1.2, 2008. View at Publisher · View at Google Scholar
  23. T. Kenakin, “What is pharmacological “affinity”? Relevance to biased agonism and antagonism,” Trends in Pharmacological Sciences, vol. 35, no. 9, pp. 434–441, 2014. View at Publisher · View at Google Scholar
  24. W. Birkmayer, P. Riederer, M. B. H. Youdim, and W. Linauer, “The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil,” Journal of Neural Transmission, vol. 36, no. 3-4, pp. 303–326, 1975. View at Publisher · View at Google Scholar · View at Scopus
  25. The Parkinson Study Group, “Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease,” The New England Journal of Medicine, vol. 328, pp. 176–183, 1993. View at Publisher · View at Google Scholar
  26. J. W. Tetrud and J. W. Langston, “The effect of deprenyl (selegiline) on the natural history of Parkinson's disease,” Science, vol. 245, no. 4917, pp. 519–522, 1989. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Engberg, T. Elebring, and H. Nissbrandt, “Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons,” Journal of Pharmacology and Experimental Therapeutics, vol. 259, no. 2, pp. 841–847, 1991. View at Google Scholar · View at Scopus
  28. G. P. Reynolds, J. D. Elsworth, K. Blau, M. Sandler, A. J. Lees, and G. M. Stern, “Deprenyl is metabolized to methamphetamine and amphetamine in man,” British Journal of Clinical Pharmacology, vol. 6, no. 6, pp. 542–544, 1978. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Karoum, L. W. Chuang, T. Eisler et al., “Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment,” Neurology, vol. 32, no. 5, pp. 503–509, 1982. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Elsworth, M. Sandler, A. J. Lees, C. Ward, and G. M. Stern, “The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties,” Journal of Neural Transmission, vol. 54, no. 1-2, pp. 105–110, 1982. View at Publisher · View at Google Scholar · View at Scopus
  31. S. H. Fox, R. Katzenschlager, S.-Y. Lim et al., “The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease,” Movement Disorders, vol. 26, supplement 3, pp. S2–S41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Sommerauer, P. Rebernik, H. Reither, C. Nanoff, and C. Pifl, “The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine,” Neuropharmacology, vol. 62, no. 4, pp. 1708–1716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. P. P. Piccini, “Dopamine transporter: basic aspects and neuroimaging,” Movement Disorders, vol. 18, supplement 7, pp. S3–S8, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. J. Kuhar, “Recent biochemical studies of the dopamine transporter—a CNS drug target,” Life Sciences, vol. 62, no. 17-18, pp. 1573–1575, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. G. E. Torres, “The dopamine transporter proteome,” Journal of Neurochemistry, vol. 97, supplement 1, pp. 3–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Giros, S. El Mestikawy, L. Bertrand, and M. G. Caron, “Cloning and functional characterization of a cocaine-sensitive dopamine transporter,” FEBS Letters, vol. 295, no. 1–3, pp. 149–154, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. J. E. Kilty, D. Lorang, and S. G. Amara, “Cloning and expression of a cocaine-sensitive rat dopamine transporter,” Science, vol. 254, no. 5031, pp. 578–579, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. T. B. Usdin, E. Mezey, C. Chen, M. J. Brownstein, and B. J. Hoffman, “Cloning of the cocaine-sensitive bovine dopamine transporter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11168–11171, 1991. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Shimada, S. Kitayama, C.-L. Lin et al., “Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA,” Science, vol. 254, no. 5031, pp. 576–578, 1991. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Kawarai, H. Kawakami, Y. Yamamura, and S. Nakamura, “Structure and organization of the gene encoding human dopamine transporter,” Gene, vol. 195, no. 1, pp. 11–18, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. G. E. Torres, R. R. Gainetdinov, and M. G. Caron, “Plasma membrane monoamine transporters: structure, regulation and function,” Nature Reviews Neuroscience, vol. 4, no. 1, pp. 13–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. G. E. Torres, A. Carneiro, K. Seamans et al., “Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2731–2739, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. G. E. Torres, W.-D. Yao, A. R. Mohn et al., “Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1,” Neuron, vol. 30, no. 1, pp. 121–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. M. S. Sonders, S. J. Zhu, N. R. Zahniser, M. P. Kavanaugh, and S. G. Amara, “Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants,” Journal of Neuroscience, vol. 17, no. 3, pp. 960–974, 1997. View at Google Scholar · View at Scopus
  45. P. Sacchetti, T. R. Mitchell, J. G. Granneman, and M. J. Bannon, “Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism,” Journal of Neurochemistry, vol. 76, no. 5, pp. 1565–1572, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, “Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 7, pp. 2173–2177, 1985. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Bezard, C. E. Gross, M. C. Fournier, S. Dovero, B. Bloch, and M. Jaber, “Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter,” Experimental Neurology, vol. 155, no. 2, pp. 268–273, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. R. K. W. Schwarting and J. P. Huston, “Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae,” Progress in Neurobiology, vol. 49, no. 3, pp. 215–266, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. P. O. Allard, J. Rinne, and J. O. Marcusson, “Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type,” Brain Research, vol. 637, no. 1-2, pp. 262–266, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-M. Maloteaux, M.-A. Vanisberg, C. Laterre, F. Javoy-Agid, Y. Agid, and P. M. Laduron, “[3H]GBR 12935 binding to dopamine uptake sites: subcellular localizatio and reduction in Parkinson's disease and progressive supranuclear palsy,” European Journal of Pharmacology, vol. 156, no. 3, pp. 331–340, 1988. View at Publisher · View at Google Scholar · View at Scopus
  51. H. B. Niznik, E. F. Fogel, F. F. Fassos, and P. Seeman, “The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus,” Journal of Neurochemistry, vol. 56, no. 1, pp. 192–198, 1991. View at Publisher · View at Google Scholar · View at Scopus
  52. R. D. Blakely, H. E. Berson, R. T. Fremeau Jr. et al., “Cloning and expression of a functional serotonin transporter from rat brain,” Nature, vol. 354, no. 6348, pp. 66–70, 1991. View at Publisher · View at Google Scholar · View at Scopus
  53. B. J. Hoffman, E. Mezey, and M. J. Brownstein, “Cloning of a serotonin transporter affected by antidepressants,” Science, vol. 254, no. 5031, pp. 579–580, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Ramamoorthy, A. L. Bauman, K. R. Moore et al., “Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2542–2546, 1993. View at Publisher · View at Google Scholar · View at Scopus
  55. K.-P. Lesch, B. L. Wolozin, D. L. Murphy, and P. Riederer, “Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter,” Journal of Neurochemistry, vol. 60, no. 6, pp. 2319–2322, 1993. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Kilic and G. Rudnick, “Oligomerization of serotonin transporter and its functional consequences,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3106–3111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Chinaglia, B. Landwehrmeyer, A. Probst, and J. M. Palacios, “Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram,” Neuroscience, vol. 54, no. 3, pp. 691–699, 1993. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Pacholczyk, R. D. Blakely, and S. G. Amara, “Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter,” Nature, vol. 350, no. 6316, pp. 350–354, 1991. View at Publisher · View at Google Scholar · View at Scopus
  59. U. Friedrich and H. Bönisch, “The neuronal noradrenaline transport system of PC-12 cells: kinetic analysis of the interaction between noradrenaline, Na+ and Cl in transport,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 333, no. 3, pp. 246–252, 1986. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Kitayama, K. Morita, and T. Dohi, “Functional characterization of the splicing variants of human norepinephrine transporter,” Neuroscience Letters, vol. 312, no. 2, pp. 108–112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. A. M. Jeannotte and A. Sidhu, “Regulation of the norepinephrine transporter by α-synuclein-mediated interactions with microtubules,” European Journal of Neuroscience, vol. 26, no. 6, pp. 1509–1520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks, “Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system,” Brain, vol. 128, no. 6, pp. 1314–1322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. G. De Simoni, G. Dal Toso, F. Fodritto, A. Sokola, and S. Algeri, “Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences,” Brain Research, vol. 411, no. 1, pp. 81–88, 1987. View at Publisher · View at Google Scholar · View at Scopus
  64. N. M. Nicolaou, M. Garcia-Munoz, G. W. Arbuthnott, and D. Eccleston, “Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei,” European Journal of Pharmacology, vol. 57, no. 4, pp. 295–305, 1979. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Bhattacharyya, I. Raote, A. Bhattacharya, R. Miledi, and M. M. Panicker, “Activation, internalization, and recycling of the serotonin 2A receptor by dopamine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15248–15253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Oz, L. Zhang, A. Rotondo, H. Sun, and M. Morales, “Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors,” Synapse, vol. 50, no. 4, pp. 303–313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Rozas, I. Liste, M. J. Guerra, and J. L. Labandeira-Garcia, “Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice,” Neuroscience Letters, vol. 245, no. 3, pp. 151–154, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Maeda, K. Kannari, H. Shen et al., “Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation,” Neuroscience Letters, vol. 343, no. 1, pp. 17–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Takeuchi, H. Kimura, T. Matsuura, and Y. Sano, “Immunohistochemical demonstration of the organization of serotonin neurons in the brain of the monkey (Macaca fuscata),” Acta Anatomica, vol. 114, no. 2, pp. 106–124, 1982. View at Publisher · View at Google Scholar · View at Scopus
  70. F. C. Zhou, S. Bledsoe, and J. Murphy, “Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain,” Brain Research, vol. 556, no. 1, pp. 108–116, 1991. View at Publisher · View at Google Scholar · View at Scopus
  71. M. K. Stachowiak, J. P. Bruno, A. M. Snyder, E. M. Stricker, and M. J. Zigmond, “Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats,” Brain Research, vol. 291, no. 1, pp. 164–167, 1984. View at Publisher · View at Google Scholar · View at Scopus
  72. A. M. Snyder, M. J. Zigmond, and R. D. Lund, “Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study,” Journal of Comparative Neurology, vol. 245, no. 2, pp. 274–281, 1986. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga, “Role of serotonergic neurons in LDOPAderived extracellular dopamine in the striatum of 6OHDAlesioned rats,” NeuroReport, vol. 10, no. 3, pp. 631–634, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Maeda, K. Nagata, Y. Yoshida, and K. Kannari, “Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA,” Brain Research, vol. 1046, no. 1-2, pp. 230–233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Arai, N. Karasawa, M. Geffard, and I. Nagatsu, “l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study,” Neuroscience Letters, vol. 195, no. 3, pp. 195–198, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Arai, N. Karasawa, M. Geffard, T. Nagatsu, and I. Nagatsu, “Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase,” Brain Research, vol. 667, no. 2, pp. 295–299, 1994. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Yamada, Y. Aimi, I. Nagatsu, K. Taki, M. Kudo, and R. Arai, “Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats,” Neuroscience Research, vol. 59, no. 1, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Carta, T. Carlsson, D. Kirik, and A. Björklund, “Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats,” Brain, vol. 130, no. 7, pp. 1819–1833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, “Involvement of the serotonin system in l-dopa-induced dyskinesias,” Parkinsonism and Related Disorders, vol. 14, no. 2, pp. S154–S158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, “Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias,” Progress in Brain Research, vol. 172, pp. 465–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Berger and J. Glowinski, “Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures,” Brain Research, vol. 147, no. 1, pp. 29–45, 1978. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Berger, “In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex,” Advances in Biochemical Psychopharmacology, vol. 19, pp. 405–408, 1978. View at Google Scholar · View at Scopus
  83. P. J. Gresch, A. F. Sved, M. J. Zigmond, and J. M. Finlay, “Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex,” Journal of Neurochemistry, vol. 65, no. 1, pp. 111–116, 1995. View at Google Scholar · View at Scopus
  84. E. Carboni, G. L. Tanda, R. Frau, and G. Di Chiara, “Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals,” Journal of Neurochemistry, vol. 55, no. 3, pp. 1067–1070, 1990. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Pozzi, R. Invernizzi, L. Cervo, F. Vallebuona, and R. Samanin, “Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats,” Journal of Neurochemistry, vol. 63, no. 1, pp. 195–200, 1994. View at Google Scholar · View at Scopus
  86. J. A. Morón, A. Brockington, R. A. Wise, B. A. Rocha, and B. T. Hope, “Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines,” The Journal of Neuroscience, vol. 22, no. 2, pp. 389–395, 2002. View at Google Scholar · View at Scopus
  87. A. Arai, M. Tomiyama, K. Kannari et al., “Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter,” Synapse, vol. 62, no. 8, pp. 632–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. E. S. Vizi, G. Zsilla, M. G. Caron, and J. P. Kiss, “Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors,” The Journal of Neuroscience, vol. 24, no. 36, pp. 7888–7894, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. I. H. Richard and R. Kurlan, “A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group,” Neurology, vol. 49, no. 4, pp. 1168–1170, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Chen, H. C. Kales, D. Weintraub, F. C. Blow, L. Jiang, and A. M. Mellow, “Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample,” Journal of Geriatric Psychiatry and Neurology, vol. 20, no. 3, pp. 161–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. D. A. M. C. van de Vijver, R. A. C. Roos, P. A. F. Jansen, A. J. Porsius, and A. de Boer, “Start of antidepressant drugs in parkinson's disease: association with the disease and its course,” International Journal of Geriatric Psychopharmacology, vol. 2, no. 3, pp. 148–152, 2000. View at Google Scholar · View at Scopus
  92. N. M. Malek, K. A. Grosset, D. Stewart, G. J. A. Macphee, and D. G. Grosset, “Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 19, no. 6, pp. 586–589, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. T. H. Chung, K. H. O. Deane, S. Ghazi-Noori, H. Rickards, and C. E. Clarke, “Systematic review of antidepressant therapies in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 10, no. 2, pp. 59–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Weintraub, K. H. Morales, P. J. Moberg et al., “Antidepressant studies in Parkinson's disease: a review and meta-analysis,” Movement Disorders, vol. 20, no. 9, pp. 1161–1169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Skapinakis, E. Bakola, G. Salanti, G. Lewis, A. P. Kyritsis, and V. Mavreas, “Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials,” BMC Neurology, vol. 10, article 49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. R. D. Dobkin, M. Menza, K. L. Bienfait et al., “Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management,” The American Journal of Geriatric Psychiatry, vol. 19, no. 3, pp. 222–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. I. H. Richard, M. P. McDermott, R. Kurlan et al., “A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease,” Neurology, vol. 78, no. 16, pp. 1229–1236, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Perez-Lloret and O. Rascol, “Parkinson disease: serotonin reuptake inhibitors for depression in PD,” Nature Reviews Neurology, vol. 8, no. 7, pp. 365–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Voon, S. Fox, T. R. Butler, and A. E. Lang, “Antidepressants and psychosis in Parkinson disease: a case series,” International Journal of Geriatric Psychiatry, vol. 22, no. 6, pp. 601–604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. V. Voon and A. E. Lang, “Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease,” Clinical Neuropharmacology, vol. 27, no. 2, pp. 90–92, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. R. J. Leo, “Movement disorders associated with the serotonin selective reuptake inhibitors,” The Journal of Clinical Psychiatry, vol. 57, no. 10, pp. 449–454, 1996. View at Publisher · View at Google Scholar · View at Scopus
  102. I. H. Richard, R. Kurlan, C. Tanner et al., “Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease,” Neurology, vol. 48, no. 4, pp. 1070–1077, 1997. View at Publisher · View at Google Scholar · View at Scopus
  103. J. L. Ritter and B. Alexander, “Retrospective study of selegiline-antidepressant drug interactions and a review of the literature,” Annals of Clinical Psychiatry, vol. 9, no. 1, pp. 7–13, 1997. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Ghosh, J. Winslow, C. Musleh, C. Gandhy, L. Bahroo, and F. Pagan, “The tolerability of rasagiline when used concurrently with serotonin reuptake inhibitors in Parkinson's disease: a retrospective analysis,” Movement Disorders, vol. 25, supplement 2, article S400, 2010. View at Google Scholar
  105. E. B. Montgomery and M. Panisset, “Retrospective statistical analysis of the incidence of serotonin toxicity in patients taking rasagiline and anti-depressants in clinical trials,” Movement Disorders, vol. 24, supplement 1, article S360, 2009. View at Google Scholar
  106. M. Panisset, J. J. Chen, L. Linda, and S. Rhyee, “Assessing the occurrence of serotonin toxicity in Parkinson's disease patients receiving rasagiline and antidepressants,” Neurology, vol. 76, supplement 4, article A539, 2011. View at Google Scholar
  107. M. Panisset, J. J. Chen, and S. H. Rhyhee, “Parkinson's disease patients treated with rasagiline and antidepressants: assessing the occurrence of serotonin toxicity,” Movement Disorders, vol. 26, supplement 2, pp. S284–S285, 2011. View at Google Scholar
  108. D. M. Weiss, “Serotonin syndrome in Parkinson disease,” The Journal of the American Board of Family Practice, vol. 8, no. 5, pp. 400–402, 1995. View at Google Scholar · View at Scopus
  109. S. C. Toyama and R. P. Iacono, “Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?” Annals of Pharmacotherapy, vol. 28, no. 3, pp. 405–406, 1994. View at Google Scholar · View at Scopus
  110. D. M. Jermain, P. L. Hughes, and A. B. Follender, “Potential fluoxetine-selegiline interaction,” Annals of Pharmacotherapy, vol. 26, no. 10, p. 1300, 1992. View at Google Scholar · View at Scopus
  111. A. Esquivel Lopez, “Serotonin syndrome induced by rasagiline [abstract],” Movement Disorders, vol. 28, supplement 1, p. S219, 2013. View at Publisher · View at Google Scholar
  112. N. Kaur, R. Madan, and A. Sharma, “Successful use of rasagiline in combination with two antidepressants: a case report,” Innovations in Clinical Neuroscience, vol. 9, no. 11-12, pp. 39–41, 2012. View at Google Scholar · View at Scopus
  113. Z. Rihmer, M. Sátori, and P. Pestality, “Selegiline-citalopram combination in patients with Parkinson's disease and major depression,” International Journal of Psychiatry in Clinical Practice, vol. 4, no. 2, pp. 123–125, 2000. View at Publisher · View at Google Scholar · View at Scopus
  114. K. M. Smith, E. Eyal, S. Xie, and D. Weintraub, “Combined rasagiline and antidepressant use in Parkinson’s disease in the ADAGIO study: effects on non-motor symptoms and tolerability,” Movement Disorders, vol. 29, supplement 1, pp. S266–S267, 2014. View at Google Scholar
  115. P. Huot and S. H. Fox, “The serotonergic system in motor and non-motor manifestations of Parkinson's disease,” Experimental Brain Research, vol. 230, no. 4, pp. 463–476, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. D. Bega, P. Schmidt, S. Wu, O. Oguh, and T. Simuni, “The utilization of antidepressants and mental health services in patients with Parkinson’s disease (PD) and depression,” Movement Disorders, vol. 29, supplement 1, p. S311, 2014. View at Google Scholar
  117. NCT00955604, http://www.clinicaltrials.gov/.
  118. M. Gony, M. Lapeyre-Mestre, and J. L. Montastruc, “Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs,” Clinical Neuropharmacology, vol. 26, no. 3, pp. 142–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. K. L. Paumier, A. J. Siderowf, C. E. Sortwell et al., “Chronic antidepressant treatment and the nigrostriatal system: the impact of antidepressant-mediated neuroplasticity [Abstract],” Society for Neuroscience, 2010.
  120. K. L. Paumier, A. D. Siderowf, P. Auinger, D. Oakes, A. J. Espay, and F. J. Revilla, “Antidepressant treatment may have disease modifying-effects in early Parkinson's disease: a patient-level meta-analysis [abstract],” Movement Disorders, vol. 25, no. 1, p. 111, 2010. View at Google Scholar
  121. S. Fahn and R. L. Elton, “Unified Parkinson's disease rating scale,” in Recent Developments in Parkinson's Disease, S. Fahn, C. D. Marsden, M. Goldstein, and D. B. Calne, Eds., pp. 153–163, Macmillan Healthcare Information, Florham Park, NJ, USA, 1987. View at Google Scholar
  122. C. G. Goetz, B. C. Tilley, S. R. Shaftman et al., “Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results,” Movement Disorders, vol. 23, no. 15, pp. 2129–2170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. K. L. Paumier, A. D. Siderowf, P. Auinger et al., “Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease,” Movement Disorders, vol. 27, no. 7, pp. 880–887, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. J. G. P. Pires, V. Bonikovski, and H. A. Futuro-Neto, “Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice,” Brazilian Journal of Medical and Biological Research, vol. 38, no. 12, pp. 1867–1872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. D. A. M. C. van de Vijver, R. A. C. Roos, P. A. F. Jansen, A. J. Porsius, and A. de Boer, “Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa,” British Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 168–170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. E. Morelli, M. S. Ansorge, and J. A. Gingrich, “5-HT transporter blockade reduces nigrostriatal dopamine signalling through 5-HT2C receptor activation to impair basal ganglia function in mice,” Society for Neuroscience, 2010, [Abstract]. View at Google Scholar
  127. H. Yamato, K. Kannari, H. Shen, T. Suda, and M. Matsunaga, “Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum,” NeuroReport, vol. 12, no. 6, pp. 1123–1126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. M. J. Owens, D. L. Knight, and C. B. Nemeroff, “Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine,” Biological Psychiatry, vol. 50, no. 5, pp. 345–350, 2001. View at Publisher · View at Google Scholar · View at Scopus
  129. N. Narita, K. Hashimoto, S.-I. Tomitaka, and Y. Minabe, “Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain,” European Journal of Pharmacology, vol. 307, no. 1, pp. 117–119, 1996. View at Publisher · View at Google Scholar · View at Scopus
  130. M. A. Paquette, K. Foley, E. G. Brudney, C. K. Meshul, S. W. Johnson, and S. P. Berger, “The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism,” Psychopharmacology, vol. 204, no. 4, pp. 743–754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. M. A. Paquette, E. G. Brudney, D. B. Putterman, C. K. Meshul, S. W. Johnson, and S. P. Berger, “Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias,” NeuroReport, vol. 19, no. 1, pp. 111–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Laloux, P. Derambure, J.-M. Jacquesson, R. Bordet, A. Destée, and C. Monaca, “The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice,” Brain Research, vol. 1161, no. 1, pp. 79–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. W.-L. Kuan, J.-W. Zhao, and R. A. Barker, “The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram,” Psychopharmacology, vol. 197, no. 2, pp. 279–293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. C. Bishop, J. A. George, W. Buchta et al., “Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats,” European Journal of Neuroscience, vol. 36, no. 6, pp. 2839–2848, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. D. Lindenbach, N. Palumbo, C. Y. Ostock, N. Vilceus, M. M. Conti, and C. Bishop, “Side effect profile of serotoninergic treatments for Parkinson's disease and L-DOPA-induced dyskinesia in hemi-Parkinsonian rats,” Movement Disorders, vol. 29, supplement 1, p. S143, 2014, [Abstract]. View at Google Scholar
  136. A. A. Goldenberg, A. Katzman, E. Kampton, M. A. Conti, D. Lindenbach, and C. Bishop, Selective Serotonin Reuptake Inhibitors Prevent Expression and Emergence of L-DOPA-Induced Dyskinesia in the Hemiparkinsonian Rat, Society for Neuroscience, 2012.
  137. M. M. Conti, C. Y. Ostock, D. Lindenbach et al., “Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats,” Neuropharmacology, vol. 77, pp. 1–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Mazzucchi, D. Frosini, E. Unti et al., “Can serotoninergic antidepressants prevent or delay the development of L-dopa induced dyskinesias in PD patients?” Movement Disorders, vol. 28, supplement 1, p. S217, 2013. View at Google Scholar
  139. R. L. Pagano, E. T. Fonoff, M. B. Berzuino, and A. P. Campos, “Parkinson disease and pain: Bioaminergic modulation on nociceptive plasticity in hemiparkinsonian rats [Abstract],” Society for Neuroscience, 2013.
  140. G. Linazasoro, “Worsening of Parkinson's disease by citalopram,” Parkinsonism and Related Disorders, vol. 6, no. 2, pp. 111–113, 2000. View at Publisher · View at Google Scholar · View at Scopus
  141. A. P. Wand, “Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression,” The Australian and New Zealand Journal of Psychiatry, vol. 46, no. 2, p. 178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. W. P. Kaschka, A. Meyer, K. R. Schier, and W. Fröscher, “Treatment of pathological crying with citalopram,” Pharmacopsychiatry, vol. 34, no. 6, pp. 254–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  143. C. Stadtland, A. Erfurth, and V. Arolt, “De Novo onset of Parkinson's disease after antidepressant treatment with citalopram,” Pharmacopsychiatry, vol. 33, no. 5, pp. 194–195, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. M. Menza, H. Marin, K. Kaufman, M. Mark, and M. Lauritano, “Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 16, no. 3, pp. 315–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Wermuth, P. S. Sørensen, S. Timm et al., “Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial,” Nordic Journal of Psychiatry, vol. 52, no. 2, pp. 163–169, 1998. View at Publisher · View at Google Scholar · View at Scopus
  146. D. Devos, K. Dujardin, I. Poirot et al., “Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study,” Movement Disorders, vol. 23, no. 6, pp. 850–857, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. D. Devos, I. Poirot, K. Dujardin et al., “Rapid efficacy of a noradrenergic reuptake inhibitor in depression in advanced Parkinson's disease: a double-blind, randomized, placebo-controlled study,” Movement Disorders, vol. 22, supplement 16, article S224, 2007. View at Google Scholar
  148. L. Rampello, S. Chiechio, R. Raffaele, I. Vecchio, and F. Nicoletti, “The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa,” Clinical Neuropharmacology, vol. 25, no. 1, pp. 21–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. S. E. Palhagen, S. Ekberg, J. Walinder, A. K. Granerus, and G. Granerus, “HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment,” Journal of Neurology, vol. 256, no. 9, pp. 1510–1518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. S. E. Pålhagen, M. Carlsson, E. Curman, J. Wålinder, and A.-K. Granérus, “Depressive illness in Parkinson's disease—indication of a more advanced and widespread neurodegenerative process?” Acta Neurologica Scandinavica, vol. 117, no. 5, pp. 295–304, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Pålhagen, H. Qi, B. Mårtensson, J. Wålinder, A.-K. Granérus, and P. Svenningsson, “Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression,” Journal of Neurology, vol. 257, no. 4, pp. 524–532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. B. Scholtissen, F. R. J. Verhey, J. J. Adam, W. Weber, and A. F. G. Leentjens, “Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance,” Clinical Neuropharmacology, vol. 29, no. 5, pp. 276–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  153. G. Dell'Agnello, R. Ceravolo, A. Nuti et al., “SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study,” Clinical Neuropharmacology, vol. 24, no. 4, pp. 221–227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  154. Z. Ye, E. Altena, C. Nombela et al., “Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease,” Brain, vol. 137, no. 4, pp. 1145–1155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. K. Seppi, D. Weintraub, M. Coelho et al., “The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease,” Movement Disorders, vol. 26, supplement 3, pp. S42–S80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. D. Weintraub, D. Taraborelli, K. H. Morales, J. E. Duda, I. R. Katz, and M. B. Stern, “Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study,” The Journal of Neuropsychiatry and Clinical Neurosciences, vol. 18, no. 3, pp. 377–383, 2006. View at Google Scholar · View at Scopus
  157. S. Varanese, H. Hamid, S. Hirsh et al., “Safety and preliminary efficacy evaluation of SAM-e and escitalopram in the treatment of depression associated with PD,” Neurology, vol. 76, supplement 4, p. A541, 2011, [Abstract]. View at Google Scholar
  158. A. C. B. Liso and C. T. Miazza, “Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram,” Farmacia Hospitalaria, vol. 33, no. 3, pp. 173–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Zarubova, M. Vyhnalek, and E. Ruzicka, “2.287 escitalopram induced psychotic episode in Parkinson's disease: a case report,” Parkinsonism & Related Disorders, vol. 13, supplement 2, article S121, 2007. View at Publisher · View at Google Scholar
  160. M. J. Millan, A. Gobert, F. Lejeune et al., “S33005, a novel ligand at both serotonin and norepinephrine transporters. I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 2, pp. 565–580, 2001. View at Google Scholar · View at Scopus
  161. M. Ruat, E. Traiffort, R. Leurs et al., “Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 18, pp. 8547–8551, 1993. View at Publisher · View at Google Scholar · View at Scopus
  162. C. Bishop, A. Kuberka, M. Mohamed, S. Eissa, D. Lindenbach, and A. Goldenberh, “Effects of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-Parkinsonian rats,” Movement Disorders, vol. 29, supplement 1, article S135, 2014. View at Google Scholar
  163. G. Meco and S. Bernardi, “Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 1, pp. 311–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. B. H. Boer, R. A. M. Erdman, H. J. V. C. Onstenk, and J. P. T. Schut, “Clomipramine, depression and Parkinson's disease,” TPSYCHIAT, vol. 18, pp. 499–509, 1976. View at Google Scholar
  165. F. P. Bymaster, L. J. Dreshfield-Ahmad, P. G. Threlkeld et al., “Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors,” Neuropsychopharmacology, vol. 25, no. 6, pp. 871–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  166. P. J. Sumner, R. Mills, F. Amjad, and F. Pagan, “Effect of a serotonin-norepinephrine reuptake inhibitor on DAT scan interpretation: a case report,” Movement Disorders, vol. 29, supplement 1, pp. S147–S148, 2014. View at Google Scholar
  167. R. Djaldetti, S. Yust-Katz, V. Kolianov, E. Melamed, and R. Dabby, “The effect of duloxetine on primary pain symptoms in Parkinson disease,” Clinical Neuropharmacology, vol. 30, no. 4, pp. 201–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  168. E. B. Lucassen and I. Richard, “Study of duloxetine for depression in Parkinson's disease,” in Proceedings of the 8th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease and Related Disorders, Berlin, Germany, 2012.
  169. U. Bonuccelli, G. Meco, G. Fabbrini et al., “A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease,” Expert Opinion on Pharmacotherapy, vol. 13, no. 16, pp. 2269–2280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  170. L. Scarzella, G. Scarzella, A. Costanza, M. di Stasi, and K. Vastola, “Duloxetine versus sertraline in treatment of depression in Parkinson's disease,” Movement Disorders, vol. 23, supplement 1, article S200, 2008. View at Google Scholar
  171. R. B. Rothman, R. D. Clark, J. S. Partilla, and M. H. Baumann, “(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters,” The Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 1191–1199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  172. R. B. Rothman, M. H. Baumann, J. E. Savage et al., “Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications,” Circulation, vol. 102, no. 23, pp. 2836–2841, 2000. View at Publisher · View at Google Scholar · View at Scopus
  173. T. Xie, L. Tong, M. W. McLane et al., “Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2639–2651, 2006. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Inden, D. Kim, Y. Gu et al., “Pharmacological characteristics of rotational behavior in hemiparkinsonian rats transplanted with mouse embryonic stem cell-derived neurons,” Journal of Pharmacological Sciences, vol. 96, no. 1, pp. 53–64, 2004. View at Publisher · View at Google Scholar · View at Scopus
  175. C. Bishop, J. L. Taylor, D. M. Kuhn, K. L. Eskow, J. Y. Park, and P. D. Walker, “MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation,” European Journal of Neuroscience, vol. 23, no. 10, pp. 2669–2676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  176. E. Shin, J. Garcia, C. Winkler, A. Björklund, and M. Carta, “Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease,” Neurobiology of Disease, vol. 47, no. 3, pp. 393–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. K. McFarland, D. L. Price, and D. W. Bonhaus, “Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease,” Behavioural Pharmacology, vol. 22, no. 7, pp. 681–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. V. S. Kostić, D. Lečić, M. Doder, J. Marinković, and S. Filipović, “Prolactin and cortisol responses to fenfluramine in Parkinson's disease,” Biological Psychiatry, vol. 40, no. 8, pp. 769–775, 1996. View at Publisher · View at Google Scholar · View at Scopus
  179. R. Volpi, P. Caffarra, S. Boni et al., “ACTH/cortisol involvement in the serotonergic disorder affecting the Parkinsonian brain,” Neuropsychobiology, vol. 35, no. 2, pp. 73–78, 1997. View at Publisher · View at Google Scholar · View at Scopus
  180. B. L. Beasley, R. W. Davenport, and T. N. Chase, “Fenfluramine hydrochloride treatment of Parkinsonism,” Archives of Neurology, vol. 34, no. 4, pp. 255–256, 1977. View at Publisher · View at Google Scholar · View at Scopus
  181. D. T. Wong, F. P. Bymaster, L. R. Reid, and P. G. Threlkeld, “Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors,” Biochemical Pharmacology, vol. 32, no. 7, pp. 1287–1293, 1983. View at Publisher · View at Google Scholar · View at Scopus
  182. P. Benfield, R. C. Heel, and S. P. Lewis, “Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness,” Drugs, vol. 32, no. 6, pp. 481–508, 1986. View at Publisher · View at Google Scholar · View at Scopus
  183. T. N. Taylor, W. M. Caudle, K. R. Shepherd et al., “Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity,” Journal of Neuroscience, vol. 29, no. 25, pp. 8103–8113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  184. S. Alter, T. N. Taylor, K. R. Shepherd, and G. W. Miller, “Serotonergic dysfunction in the VMAT2-deficient Parkinson's disease mouse model [Abstract],” Society for Neuroscience, 2010. View at Google Scholar
  185. S. Alter, T. N. Taylor, M. Wang, and G. W. Miller, “Serotonergic disruptions in the VMAT2-deficient mouse model of PD,” Society for Neuroscience, 2013, [Abstract]. View at Google Scholar
  186. R. D. Porsolt, M. Le Pichon, and M. Jalfre, “Depression: a new animal model sensitive to antidepressant treatments,” Nature, vol. 266, no. 5604, pp. 730–732, 1977. View at Publisher · View at Google Scholar · View at Scopus
  187. C. Miguelez, L. Grandoso, and L. Ugedo, “Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease,” International Journal of Neuropsychopharmacology, vol. 14, no. 2, pp. 187–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. H. Sharifi, A. M. Nayebi, and S. Farajnia, “Dose-dependent effect of flouxetine on 6-OHDA-induced catalepsy in male rats: a possible involvement of 5-HT1A receptors,” Advanced Pharmaceutical Bulletin, vol. 3, no. 1, pp. 203–206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  189. G. U. Höglinger, P. Rizk, M. P. Muriel et al., “Dopamine depletion impairs precursor cell proliferation in Parkinson disease,” Nature Neuroscience, vol. 7, no. 7, pp. 726–735, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. K. Suzuki, K. Okada, T. Wakuda et al., “Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine,” PLoS ONE, vol. 5, no. 2, Article ID e9260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. Z. Kohl, B. Winner, K. Ubhi et al., “Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model,” European Journal of Neuroscience, vol. 35, no. 1, pp. 10–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. Z. Kohl, B. Winner, M. Mante et al., “Impaired adult hippocampal neurogenesis in the A53T Parkinson disease mouse model is restored by chronic oral fluoxetine treatment,” Society for Neuroscience, 2011, Poster 884.12/Z4. View at Google Scholar
  193. A. Bédard, C. Gravel, and A. Parent, “Chemical characterization of newly generated neurons in the striatum of adult primates,” Experimental Brain Research, vol. 170, no. 4, pp. 501–512, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. A. Bédard, M. Cossette, M. Lévesque, and A. Parent, “Proliferating cells can differentiate into neurons in the striatum of normal adult monkey,” Neuroscience Letters, vol. 328, no. 3, pp. 213–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  195. Y. C. Chung, S. R. Kim, J.-Y. Park et al., “Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation,” Neuropharmacology, vol. 60, no. 6, pp. 963–974, 2011. View at Publisher · View at Google Scholar · View at Scopus
  196. F. Zhang, H. Zhou, B. C. Wilson, J.-S. Shi, J.-S. Hong, and H.-M. Gao, “Fluoxetine protects neurons against microglial activation-mediated neurotoxicity,” Parkinsonism and Related Disorders, vol. 18, supplement 1, pp. S213–S217, 2012. View at Google Scholar · View at Scopus
  197. S. Djordjevic, I. Kovacevic, B. Miljkovic, J. Vuksanovic, and M. Pokrajac, “Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study,” Farmaco, vol. 60, no. 4, pp. 345–349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  198. I. Kovacevic, M. Pokrajac, B. Miljkovic, D. Jovanovic, and M. Prostran, “Comparison of liquid chromatography with fluorescence detection to liquid chromatography-mass spectrometry for the determination of fluoxetine and norfluoxetine in human plasma,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 830, no. 2, pp. 372–376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  199. J. J. Huszonek, “Anticholinergic effects in a depressed parkinsonian patient,” Journal of Geriatric Psychiatry and Neurology, vol. 8, no. 2, pp. 100–102, 1995. View at Publisher · View at Google Scholar · View at Scopus
  200. E. N. H. J. Steur, “Increase of Parkinson disability after fluoxetine medication,” Neurology, vol. 43, no. 1, pp. 211–213, 1993. View at Publisher · View at Google Scholar · View at Scopus
  201. Y. Xia, H.-D. Wang, Y. Ding, B. Kang, and W.-G. Liu, “Parkinson's disease combined with depression treated with electroacupuncture and medication and its effect on serum BDNF,” Chinese Acupuncture & Moxibustion, vol. 32, no. 12, pp. 1071–1074, 2012. View at Google Scholar · View at Scopus
  202. E. F. Cardoso, F. Fregni, F. Martins Maia et al., “rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex,” International Journal of Neuropsychopharmacology, vol. 11, no. 2, pp. 173–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  203. F. Fregni, C. M. Santos, M. L. Myczkowski et al., “Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 8, pp. 1171–1174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  204. E. Dzoljic, Z. Todorovic, M. Mijajlovic et al., “Fluoxetine does not impair motor function in patients with Parkinson's disease,” Movement Disorders, vol. 24, supplement 1, p. S350, 2009. View at Google Scholar
  205. B. Trappler and S. Friedman, “Treatment of depression in Parkinson's disease in the very old,” Journal of Pharmacy Technology, vol. 14, no. 3, pp. 110–115, 1998. View at Google Scholar · View at Scopus
  206. P. S. Boggio, F. Fregni, F. Bermpohl et al., “Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression,” Movement Disorders, vol. 20, no. 9, pp. 1178–1184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  207. F. Fregni, C. R. Ono, C. M. Santos et al., “Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD,” Neurology, vol. 66, no. 11, pp. 1629–1637, 2006. View at Publisher · View at Google Scholar · View at Scopus
  208. F. Durif, M. Vidailhet, A. M. Bonnet, J. Blin, and Y. Agid, “Levodopa-induced dyskinesias are improved by fluoxetine,” Neurology, vol. 45, no. 10, pp. 1855–1858, 1995. View at Publisher · View at Google Scholar · View at Scopus
  209. E. M. Gatto, M. Fernandez Pardal, and F. Micheli, “Exacerbation of parkinsonism caused by fluoxetine,” Medicina, vol. 54, article 182, 1994. View at Google Scholar
  210. M. R. Lemke, “Reboxetine treatment of depression in Parkinson's disease,” Journal of Clinical Psychiatry, vol. 61, no. 11, p. 872, 2000. View at Google Scholar · View at Scopus
  211. J. A. Simons, “Fluoxetine in Parkinson's disease,” Movement Disorders, vol. 11, no. 5, pp. 581–582, 1996. View at Publisher · View at Google Scholar · View at Scopus
  212. J.-L. Montastruc, N. Fabre, O. Blin, J.-M. Senard, O. Rascol, and A. Rascol, “Does fluoxetine aggravate Parkinson's disease? A pilot prospective study,” Movement Disorders, vol. 10, no. 3, pp. 355–357, 1995. View at Publisher · View at Google Scholar · View at Scopus
  213. C. F. Caley and J. H. Friedman, “Does fluoxetine exacerbate Parkinson's disease?” Journal of Clinical Psychiatry, vol. 53, no. 8, pp. 278–282, 1992. View at Google Scholar · View at Scopus
  214. J. H. Friedman, “Fluoxetine in Parkinson's disease,” Movement Disorders, vol. 7, supplement 1, p. 102, 1992. View at Google Scholar
  215. N. D. Demchuk and A. A. Shutov, “Correction of motor and affective symptoms of parkinsonism by selective serotonine reuptake inhibition antidepressant,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 108, no. 9, pp. 29–35, 2008. View at Google Scholar · View at Scopus
  216. V. Kostić, E. Džoljić, Z. Todorović et al., “Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine,” Vojnosanitetski Pregled, vol. 69, no. 12, pp. 1067–1075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  217. E. C. Lauterbach, “Dopaminergic hallucinosis with fluoxetine in Parkinson's disease,” American Journal of Psychiatry, vol. 150, no. 11, p. 1750, 1993. View at Google Scholar · View at Scopus
  218. J. L. Montastruc, M. Pelat, P. Verwaerde et al., “Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study,” Fundamental & Clinical Pharmacology, vol. 12, no. 4, pp. 398–402, 1998. View at Publisher · View at Google Scholar · View at Scopus
  219. J. C. Garcia-Monco, A. Padierna, and M. G. Beldarrain, “Selegiline, fluoxetine, and depression in Parkinson's disease,” Movement Disorders, vol. 10, no. 3, article 352, 1995. View at Publisher · View at Google Scholar · View at Scopus
  220. O. Suchowerksy and J. D. de Vries, “Interaction of fluoxetine and selegiline,” Canadian Journal of Psychiatry, vol. 35, no. 6, pp. 571–572, 1990. View at Google Scholar · View at Scopus
  221. J. L. Montastruc, B. Chamontin, J. M. Senard et al., “Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline,” The Lancet, vol. 341, no. 8844, article 555, 1993. View at Google Scholar · View at Scopus
  222. C. H. Waters, “Fluoxetine and selegiline—lack of significant interaction,” Canadian Journal of Neurological Sciences, vol. 21, no. 3, pp. 259–261, 1994. View at Google Scholar · View at Scopus
  223. V. Claassen, “Review of the animal pharmacology and pharmacokinetics of fluvoxamine,” British Journal of Clinical Pharmacology, vol. 15, supplement 3, pp. 349S–355S, 1983. View at Google Scholar · View at Scopus
  224. E. L. Lane, S. Cheetham, and P. Jenner, “Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 3, pp. 1124–1131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. M. Nomoto and S. Iwata, “Functions and metabolic rates of transmitters in the basal ganglia,” Nippon Rinsho, vol. 58, no. 10, pp. 1987–1993, 2000. View at Google Scholar · View at Scopus
  226. A. S. Gonul and M. Aksu, “SSRI-induced parkinsonism may be an early sign of future Parkinson's disease,” Journal of Clinical Psychiatry, vol. 60, no. 6, article 410, 1999. View at Publisher · View at Google Scholar · View at Scopus
  227. D. Aarsland, J. P. Larsen, O. Waage, and J. H. Langeveld, “Maintenance electroconvulsive therapy for Parkinson's disease,” Convulsive Therapy, vol. 13, no. 4, pp. 274–277, 1997. View at Google Scholar · View at Scopus
  228. K. Toda, T. Harada, F. Ishizaki, N. Horie, and T. Yamada, “Parkinson disease patient with fibromyalgia: a case report,” Parkinsonism and Related Disorders, vol. 13, no. 5, pp. 312–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  229. E. F. McCance-Katz, K. L. Marek, and L. H. Price, “Serotonergic dysfunction in depression associated with Parkinson's disease,” Neurology, vol. 42, no. 9, pp. 1813–1814, 1992. View at Publisher · View at Google Scholar · View at Scopus
  230. J. D. Meerwaldt, “Treatment of hypokinetic rigid syndrome with fluvoxamine maleate,” The Lancet, vol. 1, no. 8487, pp. 977–978, 1986. View at Google Scholar · View at Scopus
  231. G. Meco, V. Bonifati, E. Fabrizio, and N. Vanacore, “Worsening of parkinsonism with fluvoxamine—two cases,” Human Psychopharmacology, vol. 9, no. 6, pp. 439–441, 1994. View at Publisher · View at Google Scholar · View at Scopus
  232. A. Kuno, T. Ogawa, K. Ikeguchi, K. Fujimoto, and I. Nakano, “Deterioration of parkinsonian symptoms and psychosis after fluvoxamine medication,” Neurologia Medico-Chirurgica, vol. 54, pp. 157–160, 2001. View at Google Scholar
  233. P. le Cavorzin, S. Sarkis, C. Beneton, J. F. Pinel, L. Maruelle, and P. le Vaou, “Fluvoxamine and serotonin syndrome in a patient with Parkinson disease,” Thérapie, vol. 51, no. 2, pp. 195–196, 1996. View at Google Scholar
  234. R. C. Petersen and E. Richelson, “Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells,” Psychopharmacology, vol. 76, no. 1, pp. 26–28, 1982. View at Publisher · View at Google Scholar · View at Scopus
  235. V. T. Tran, R. S. L. Chang, and S. H. Snyder, “Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 12, pp. 6290–6294, 1978. View at Publisher · View at Google Scholar · View at Scopus
  236. M. Papp, V. Klimek, and P. Willner, “Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression,” Psychopharmacology, vol. 114, no. 2, pp. 309–314, 1994. View at Publisher · View at Google Scholar · View at Scopus
  237. E. K. Lee and Y. J. Lee, “Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia,” International Journal of Clinical Pharmacy, vol. 35, no. 5, pp. 711–718, 2013. View at Publisher · View at Google Scholar · View at Scopus
  238. S. Casas, S. García, R. Cabrera, F. Nanfaro, C. Escudero, and R. Yunes, “Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats,” Pharmacology Biochemistry and Behavior, vol. 99, no. 4, pp. 614–618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  239. M. Sano, M. Stanley, A. Lawton et al., “Tritiated imipramine binding: a peripheral marker for serotonin in Parkinson's disease,” Archives of Neurology, vol. 48, no. 10, pp. 1052–1054, 1991. View at Publisher · View at Google Scholar · View at Scopus
  240. L. S. Schneider, H. C. Chui, J. A. Severson, and R. Bruce Sloane, “Decreased platelet 3H-imipramine binding in parkinson's disease,” Biological Psychiatry, vol. 24, no. 3, pp. 348–351, 1988. View at Publisher · View at Google Scholar · View at Scopus
  241. B. E. Suranyi-Cadotte, S. Gauthier, F. Lafaille et al., “Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia,” Life Sciences, vol. 37, no. 24, pp. 2305–2311, 1985. View at Publisher · View at Google Scholar · View at Scopus
  242. R. Raisman, R. Cash, and Y. Agid, “Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen,” Neurology, vol. 36, no. 4, pp. 556–560, 1986. View at Publisher · View at Google Scholar · View at Scopus
  243. R. Cash, R. Raisman, A. Ploska, and Y. Agid, “High and low affinity [3H]imipramine binding sites in control and Parkinsonian brains,” European Journal of Pharmacology, vol. 117, no. 1, pp. 71–80, 1985. View at Publisher · View at Google Scholar · View at Scopus
  244. R. B. Rosse and J. Peters, “Depression dependent parkinsonism: case report,” International Journal of Psychiatry in Medicine, vol. 16, no. 1, pp. 85–90, 1986. View at Publisher · View at Google Scholar · View at Scopus
  245. P. Schmidt, “Imipramine in Parkinsonism,” Psychiatrie, Neurologie, und medizinische Psychologie, vol. 25, pp. 631–636, 1973. View at Google Scholar
  246. L. H. Blomberg and G. Eriksson, “Imipramine (Tofranil) vid behandling av parkinsonism,” Svensk Tandläkare Tidskrift, vol. 58, pp. 2500–2503, 1968. View at Google Scholar
  247. H. Strauss, “Office treatment of depressive states with a new drug (imipramine),” New York State Journal of Medicine, vol. 59, no. 15, pp. 2906–2910, 1959. View at Google Scholar · View at Scopus
  248. R. B. Jenkins and R. H. Groh, “Mental symptoms in Parkinsonian patients treated with L-dopa,” The Lancet, vol. 2, no. 7665, pp. 177–179, 1970. View at Google Scholar · View at Scopus
  249. R. B. Jenkins and R. H. Groh, “Psychic effects in patients treated with levodopa,” Journal of the American Medical Association, vol. 212, no. 13, p. 2265, 1970. View at Publisher · View at Google Scholar · View at Scopus
  250. R. R. Strang, “Imipramine in treatment of parkinsonism: a double-blind placebo study,” British Medical Journal, vol. 2, no. 5452, pp. 33–34, 1965. View at Google Scholar · View at Scopus
  251. J. C. Denmark, J. D. David, and S. G. Mccomb, “Imipramine hydrochloride (Tofranil) in Parkinsonism. A preliminary report,” British Journal of Clinical Practice, vol. 15, pp. 523–524, 1961. View at Google Scholar · View at Scopus
  252. D. Dobrina and M. Antonini, “Imipramine in parkinsonian syndromes,” Rivista di Neurologia, vol. 32, pp. 586–604, 1962. View at Google Scholar · View at Scopus
  253. R. O. Gillhespy and D. M. Mustard, “The evaluation of imipramine in the treatment of Parkinson's disease,” The British Journal of Clinical Practice, vol. 17, pp. 205–208, 1963. View at Google Scholar · View at Scopus
  254. M. de la Herran, “Treatment of Parkinsonian syndromes with two derivates of iminodibenzil: imipramine (tofranil) and desipramine (pertrofana),” Revista Clinica Espanola, vol. 106, no. 5, pp. 390–394, 1967. View at Google Scholar · View at Scopus
  255. A. J. Mandell, C. Markham, and W. Fowler, “Parkinson's syndrome, depression and imipramine. A preliminary report,” California Medicine, vol. 95, pp. 12–14, 1961. View at Google Scholar · View at Scopus
  256. H. Lim and K. Tan, “Treatment of Parkinson syndroms with tofranil,” No To Shinkei, vol. 13, pp. 931–936, 1961. View at Google Scholar
  257. J. C. Gal, “Study of the action of imipramine on parkinsonian akinesia,” Gazette Médicale de France, vol. 67, pp. 1821–1824, 1960. View at Google Scholar · View at Scopus
  258. J. Sigwald, D. Bouttier, C. Raymondeaud, M. Marquez, and J. C. Gal, “Etude de l'action sur l'akinesie parkinsonienne de deux derives de l'iminodibenzyle: le chlorhydrate de N-(gamma-dimethylaminopropyl)-iminodibenzyle ou imipramine et le [beta-(hydroxyethyl-4′′ piperazinyl)-3′ propyl]-5 iminodibenzyle, ou 8307 RP,” La Presse Médicale, vol. 46, pp. 1697–1698, 1959. View at Google Scholar
  259. J. Sigwald, D. Bouttier, Marques, J. Basset, and J. C. Gal, “Improvement of parkinsonian akinesia by 2 iminodibenzyl derivatives,” Revue Neurologique, vol. 101, pp. 583–584, 1959. View at Google Scholar · View at Scopus
  260. J. Sigwald, “Treatment of parkinsonian akinesia,” La Semaine des Hôpitaux: Thérapeutique, vol. 37, pp. 622–623, 1961. View at Google Scholar · View at Scopus
  261. G. di Cristo and F. di Cristo-Tedeschi, “L'imipramina (G. 22355) a basso dosaggio nel trattamento della sintomatologia parkinsoniana,” Acta Neurologica, vol. 16, pp. 740–747, 1961. View at Google Scholar
  262. J. M. Espalader, M. B. Riba, J. J. Gruart, and J. P. Domenech, “Estudio clinico de la accion de la imipramina sobre la acinesia parkinsoniana,” Revista Española de Oto-Neuro-Oftalmología y Neurocirugía, vol. 24, pp. 141–149, 1965. View at Google Scholar
  263. L. Tanfani, “L'imipramina nelle sindromi parkinsoniane. Ospedale Psich,” in Symposium Rapallo, p. 475, Verona, Italy, 1960.
  264. M. Oscar-Berman, A. Gade, R. G. Feldman, and M. A. Saavedra, “Effects of dimepramine fumarate on physiological and cognitive behaviors of Parkinson patients,” Journal of Clinical Pharmacology, vol. 19, no. 10, pp. 626–634, 1979. View at Publisher · View at Google Scholar · View at Scopus
  265. J. P. Morgan, G. Nathan, L. Rivera Calimlim, and N. Trabert, “Imipramine-caused interference with levodopa absorption from the gastrointestinal tract in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 192, no. 2, pp. 451–457, 1975. View at Google Scholar · View at Scopus
  266. J. P. Morgan, L. Rivera-Calimlim, F. Messiha, P. R. Sundaresan, and N. Trabert, “Imipramine mediated interference with levodopa absorption from the gastrointestinal tract in man,” Neurology, vol. 25, no. 11, pp. 1029–1034, 1975. View at Publisher · View at Google Scholar · View at Scopus
  267. L. P. Lobova, T. A. Dobrokhotova, G. A. Mashanova, and S. N. Fedorov, “Problems of psychopharmacology in neurosurgery,” Voprosy Neĭrokhirurgii, vol. 31, no. 2, pp. 47–51, 1967. View at Google Scholar · View at Scopus
  268. H. Pakkenberg, “Pathogenesis and medical treatment of parkinsonism,” Ugeskrift for Læger, vol. 125, pp. 759–764, 1963. View at Google Scholar · View at Scopus
  269. Y. C. Chung, S. R. Kim, and B. K. Jin, “Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease,” The Journal of Immunology, vol. 185, no. 2, pp. 1230–1237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  270. M. M. Carvalho, F. L. Campos, B. Coimbra, A. J. Rodrigues, P. M. Jose, and J. M. Bessa, “The 6-OHDA model of Parkinson's disease: behavioral characterization and effects of dopaminergic and antidepressant therapy,” Society for Neuroscience.
  271. M. M. Carvalho, F. L. Campos, B. Coimbra et al., “Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits,” Molecular Neurodegeneration, vol. 8, no. 1, article 14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  272. C. P. L.-H. Chen, J. T. Alder, L. Bray, A. E. Kingsbury, P. T. Francis, and O. J. F. Foster, “Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex,” Annals of the New York Academy of Sciences, vol. 861, pp. 288–289, 1998. View at Publisher · View at Google Scholar · View at Scopus
  273. Y. Hamada, K. Miyamoto, Y. Inatsugi, H. Suzuki, and S. Kusunoki, “A case of Parkinson's disease with neuroleptic malignant syndrome induced by Paroxetine,” Rinsho Shinkeigaku, vol. 46, no. 8, pp. 575–578, 2006. View at Google Scholar · View at Scopus
  274. P. L. Freijzer and J. H. E. Brenninkmeijer, “Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation,” Nederlands Tijdschrift voor Geneeskunde, vol. 146, no. 12, pp. 574–575, 2002. View at Google Scholar · View at Scopus
  275. E. N. Steur, “Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa,” Nederlands Tijdschrift voor Geneeskunde, vol. 146, no. 22, pp. 1056–1057, 2002. View at Google Scholar
  276. C. J. M. Schölzel-Dorenbos, “Hallucinations caused by paroxetine taken together with a levdopa-carbidopa preparation,” Nederlands Tijdschrift voor Geneeskunde, vol. 146, no. 35, pp. 1663–1664, 2002. View at Google Scholar · View at Scopus
  277. R. Ceravolo, A. Nuti, A. Piccinni et al., “Paroxetine in Parkinson's disease: effects on motor and depressive symptoms,” Neurology, vol. 55, no. 8, pp. 1216–1218, 2000. View at Publisher · View at Google Scholar · View at Scopus
  278. S. Tesei, A. Antonini, M. Canesi, A. Zecchinelli, C. B. Mariani, and G. Pezzoli, “Tolerability of paroxetine in Parkinson's disease: a prospective study,” Movement Disorders, vol. 15, no. 5, pp. 986–989, 2000. View at Google Scholar
  279. W. Wittgens, O. Donath, and U. Trenckmann, “Treatment of depressive syndromes in Parkinson's disease (PD) with paroxetine,” Movement Disorders, vol. 12, supplement 1, p. 128, 1997. View at Google Scholar
  280. M. I. Tarczy and E. Szombathelyl, “Depression in Parkinson's disease with special regard to anxiety. Experiences with paroxetine treatment,” Movement Disorders, vol. 13, supplement 2, article 276, 1998. View at Google Scholar
  281. K. A. Chung, N. E. Carlson, and J. G. Nutt, “Short-term paroxetine treatment does not alter the motor response to levodopa in PD,” Neurology, vol. 64, no. 10, pp. 1797–1798, 2005. View at Publisher · View at Google Scholar · View at Scopus
  282. F. J. Jimenez-Jimenez, J. Tejeiro, G. Martinez-Junquera, F. Cabrera-Valdivia, J. Alarcon, and E. Garcia-Albea, “Parkinsonism exacerbated by paroxetine,” Neurology, vol. 44, no. 12, article 2406, 1994. View at Publisher · View at Google Scholar · View at Scopus
  283. R. Sakakibara, T. Ito, T. Uchiyama, Y. Awa, C. Yamaguchi, and T. Hattori, “Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment,” Urologia Internationalis, vol. 81, no. 3, pp. 335–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  284. R. D. Dobkin, M. Menza, K. L. Bienfait et al., “The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 2, pp. 188–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  285. M. Menza, R. DeFonzo Dobkin, H. Marin et al., “The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease,” Movement Disorders, vol. 24, no. 9, pp. 1325–1332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  286. I. H. Richard, M. McDermott, and W. M. McDonald, “A multicenter randomized, double-blind, placebo-controlled trial of paroxetine and venlafaxine extended release for depression in Parkinson’s disease [abstract],” Movement Disorders, vol. 25, supplement 3, p. s680, 2010. View at Google Scholar
  287. A. J. H. Moonen, A. Wijers, A. F. G. Leentjens et al., “Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 20, no. 6, pp. 644–646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  288. M. J. Owens, W. N. Morgan, S. J. Plott, and C. B. Nemeroff, “Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites,” Journal of Pharmacology and Experimental Therapeutics, vol. 283, no. 3, pp. 1305–1322, 1997. View at Google Scholar · View at Scopus
  289. S. Reyhani-Rad, J. Mahmoudi, M. Khanmohammadi, and S. Gahnji, “Effect of sertraline on 6-hydroxydopamine-induced catalepsy in hemi-parkinsonian rats,” Annals of Biological Research, vol. 3, pp. 3062–3066, 2012. View at Google Scholar
  290. J. P. P. Foong and J. C. Bornstein, “5-HT antagonists NAN-190 and SB 269970 block alpha2- adrenoceptors in the guinea pig,” NeuroReport, vol. 20, no. 3, pp. 325–330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  291. M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner, “Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 3, pp. 952–958, 2002. View at Publisher · View at Google Scholar · View at Scopus
  292. M. S. Okun, D. V. Raju, B. L. Walter et al., “Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 75, no. 6, pp. 921–923, 2004. View at Publisher · View at Google Scholar · View at Scopus
  293. M. S. Okun, K. M. Heilman, and J. L. Vitek, “Treatment of pseudobulbar laughter after gamma knife thalamotomy,” Movement Disorders, vol. 17, no. 3, pp. 622–624, 2002. View at Publisher · View at Google Scholar · View at Scopus
  294. M. A. P. Latorre, P. J. Modrego, F. Rodilla, C. Catalán, and M. Calvo, “Parkinsonism and Parkinson's disease associated with long-term administration of sertraline,” Journal of Clinical Pharmacy and Therapeutics, vol. 26, no. 2, pp. 111–112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  295. M. A. P. Latorre and S. Z. Lopez, “Reversible parkinsonism secondary to the use of sertraline,” Neurologia, vol. 13, no. 9, pp. 444–445, 1998. View at Google Scholar · View at Scopus
  296. R. J. Gregory and J. F. White, “Can sertraline induce parkinson's disease?” Psychosomatics, vol. 42, no. 2, pp. 163–164, 2001. View at Google Scholar · View at Scopus
  297. A. Cano and J. Roquer, “Parkinsonism secondary to the use of sertraline,” Medicina Clinica, vol. 105, no. 20, pp. 797–798, 1995. View at Google Scholar · View at Scopus
  298. R. Sandyk, “Speech impairment in Parkinson's disease is improved by trancranial application of electromagnetic fields,” International Journal of Neuroscience, vol. 92, no. 1-2, pp. 63–72, 1997. View at Publisher · View at Google Scholar · View at Scopus
  299. G. L. Dike, “Triphasic waves in serotonin syndrome,” Journal of Neurology Neurosurgery and Psychiatry, vol. 62, no. 2, p. 200, 1997. View at Google Scholar · View at Scopus
  300. C. W. Olanow, “A 61-year-old man with Parkinson's disease,” The Journal of the American Medical Association, vol. 275, no. 9, pp. 716–722, 1996. View at Publisher · View at Google Scholar · View at Scopus
  301. R. A. Hauser and T. A. Zesiewicz, “Sertraline for the treatment of depression in Parkinson's disease,” Movement Disorders, vol. 12, no. 5, pp. 756–759, 1997. View at Publisher · View at Google Scholar · View at Scopus
  302. R. A. Hauser and T. A. Zesiewicz, “Sertraline for the treatment of depression in Parkinson's disease,” Movement Disorders, vol. 12, no. 5, pp. 756–759, 1997. View at Google Scholar
  303. R. J. Meara, B. K. Bhowmick, and J. P. Hobson, “An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease,” Journal of Serotonin Research, vol. 2, no. 4, pp. 243–249, 1996. View at Google Scholar · View at Scopus
  304. J. Meara and P. Hobson, “Sertraline for the treatment of depression in Parkinson's disease,” Movement Disorders, vol. 13, no. 3, p. 622, 1998. View at Google Scholar
  305. L. M. Shulman, C. Singer, R. Liefert, T. Mellman, and W. J. Weiner, “Therapeutics effects of sertraline (Zoloft) in patients with Parkinson's disease (PD),” Movement Disorders, vol. 11, p. 603, 1996. View at Google Scholar
  306. P. Barone, L. Scarzella, R. Marconi et al., “Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study,” Journal of Neurology, vol. 253, no. 5, pp. 601–607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  307. S. Marino, E. Sessa, G. Di Lorenzo et al., “Sertraline in the treatment of depressive disorders in patients with Parkinson's disease,” Neurological Sciences, vol. 29, no. 6, pp. 391–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  308. A. Antonini, S. Tesei, A. Zecchinelli et al., “Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life,” Movement Disorders, vol. 21, no. 8, pp. 1119–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  309. J. Kulisevsky, J. Pagonabarraga, B. Pascual-Sedano, A. Gironell, C. García-Sánchez, and M. Martínez-Corral, “Motor changes during sertraline treatment in depressed patients with Parkinson's disease,” European Journal of Neurology, vol. 15, no. 9, pp. 953–959, 2008. View at Publisher · View at Google Scholar · View at Scopus
  310. A. F. G. Leentjens, F. W. Vreeling, G.-J. Luijckx, and F. R. J. Verhey, “SSRIs in the treatment of depression in Parkinson's disease,” International Journal of Geriatric Psychiatry, vol. 18, no. 6, pp. 552–554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  311. F. Duval, O. Flabeau, J. Razafimahefa, U. Spampinato, and F. Tison, “Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome,” Movement Disorders, vol. 28, no. 10, pp. 1464–1464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  312. A. L. dos Santos Werneck, A. L. Rosso, and M. B. Vincent, “The use of an antagonist 5-HT2A/C for depression and motor function in Parkinson' disease,” Arquivos de Neuro-Psiquiatria, vol. 67, no. 2, pp. 407–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  313. M. El-Awar, M. Freedman, P. Seeman, L. Goldenberg, J. Little, and P. Solomon, “Response of tardive and L-dopa-induced dyskinesias to antidepressants,” Canadian Journal of Neurological Sciences, vol. 14, no. 4, pp. 629–631, 1987. View at Google Scholar · View at Scopus
  314. G. L. Piccinin, M. Piccirilli, and L. Agostini, “Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone,” Clinica Terapeutica, vol. 96, no. 6, pp. 621–626, 1981. View at Google Scholar · View at Scopus
  315. F. Sanson, E. Schergna, D. Semenzato et al., “Effect of trazodone in treatment of tremor,” Rivista di Neurologia, vol. 56, no. 6, pp. 358–364, 1986. View at Google Scholar · View at Scopus
  316. G. Cerone, S. Ruggieri, P. Aloisi, L. Cappenberg, and A. Agnoli, “Pharmacologic study of Parkinson tremor. III. Role of the serotonin-histamine system,” Bollettino della Societa Italiana di Biologia Sperimentale, vol. 53, no. 5, pp. 354–360, 1977. View at Google Scholar · View at Scopus
  317. S. Ruggieri, G. Cerone, P. Aloisi, L. Cappenberg, and A. Agnoli, “Pharmacologic study of Parkinson tremor. I. Methodology,” Bollettino della Societa Italiana di Biologia Sperimentale, vol. 53, no. 5, pp. 344–348, 1977. View at Google Scholar · View at Scopus
  318. G. Cerone, S. Ruggieri, and A. Agnoli, “Parkinsonian tremor: a neuropharmacological study,” Acta Neurologica Belgica, vol. 77, no. 4, pp. 213–229, 1977. View at Google Scholar · View at Scopus
  319. F. Mastrosimone, C. Colucci D'Amato, G. de Angelis, C. Iaccarino, L. Giordano, and E. Marmo, “Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease,” Journal of Medicine, vol. 11, no. 5-6, pp. 377–383, 1980. View at Google Scholar · View at Scopus
  320. M. Dias and A. Antunes, “Effect of deep brain stimulation on a patient with obstructive sleep apnea and Parkinson disease: a case report,” Chest, vol. 145, no. 3, p. 570A, 2014. View at Publisher · View at Google Scholar
  321. G. Gross, X. Xin, and M. Gastpar, “Trimipramine: pharmacological reevaluation and comparison with clozapine,” Neuropharmacology, vol. 30, no. 11, pp. 1159–1166, 1991. View at Publisher · View at Google Scholar · View at Scopus
  322. L. C. Routh, J. L. Black, and J. E. Ahlskog, “Parkinson's disease complicated by anxiety,” Mayo Clinic Proceedings, vol. 62, no. 8, pp. 733–735, 1987. View at Publisher · View at Google Scholar · View at Scopus
  323. K. Bayulkem and F. Torun, “Therapeutic efficiency of venlafaxin in depressive patients with Parkinson's disease,” Movement Disorders, vol. 17, supplement 5, article S75, 2002. View at Google Scholar
  324. S. Rajapakse, L. Abeynaike, and T. Wickramarathne, “Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease,” Journal of Clinical Psychopharmacology, vol. 30, no. 5, pp. 620–622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  325. O. Bolukbasi and A. Akyol, “Spontaneous erections and libido increase associated with venlafaxine,” European Journal of Neurology, vol. 6, no. 4, pp. 527–528, 1999. View at Publisher · View at Google Scholar · View at Scopus
  326. D. C. Deecher, C. E. Beyer, G. Johnston et al., “Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 2, pp. 657–665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  327. A. Ceci, S. Garattini, M. Gobbi, and T. Mennini, “Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain,” British Journal of Pharmacology, vol. 88, no. 1, pp. 269–275, 1986. View at Publisher · View at Google Scholar · View at Scopus
  328. J.-J. Bonnet, A. Chagraoui, P. Protais, and J. Costentin, “Interactions of amineptine with the neuronal dopamine uptake system: neurochemical in vitro and in vivo studies,” Journal of Neural Transmission, vol. 69, no. 3-4, pp. 211–220, 1987. View at Publisher · View at Google Scholar · View at Scopus
  329. S. C. Cheetham, J. A. Viggers, N. A. Slater, D. J. Heal, and W. R. Buckett, “[3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments,” Neuropharmacology, vol. 32, no. 8, pp. 737–743, 1993. View at Publisher · View at Google Scholar · View at Scopus
  330. C. M. Lee, J. A. Javitch, and S. H. Snyder, “Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes,” The Journal of Neuroscience, vol. 2, no. 10, pp. 1515–1525, 1982. View at Google Scholar · View at Scopus
  331. C. Bolden-Watson and E. Richelson, “Blockade of newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes,” Life Sciences, vol. 52, no. 12, pp. 1023–1029, 1993. View at Publisher · View at Google Scholar · View at Scopus
  332. E. Richelson and M. Pfenning, “Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake,” European Journal of Pharmacology, vol. 104, no. 3-4, pp. 277–286, 1984. View at Publisher · View at Google Scholar · View at Scopus
  333. P. J. Goodnick and B. J. Goldstein, “Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology,” Journal of Psychopharmacology, vol. 12, pp. S5–S20, 1998. View at Google Scholar · View at Scopus
  334. M. Tatsumi, K. Groshan, R. D. Blakely, and E. Richelson, “Pharmacological profile of antidepressants and related compounds at human monoamine transporters,” European Journal of Pharmacology, vol. 340, no. 2-3, pp. 249–258, 1997. View at Publisher · View at Google Scholar · View at Scopus
  335. J. Hyttel, “Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs),” International Clinical Psychopharmacology, vol. 9, no. 1, pp. 19–26, 1994. View at Publisher · View at Google Scholar · View at Scopus
  336. J. Hyttel, “Citalopram—pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 6, no. 3, pp. 277–295, 1982. View at Publisher · View at Google Scholar · View at Scopus
  337. S. N. Vaishnavi, C. B. Nemeroff, S. J. Plott, S. G. Rao, J. Kranzler, and M. J. Owens, “Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity,” Biological Psychiatry, vol. 55, no. 3, pp. 320–322, 2004. View at Publisher · View at Google Scholar · View at Scopus
  338. D. D. Han and H. H. Gu, “Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs,” BMC Pharmacology, vol. 6, article 6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  339. F. P. Bymaster, J. S. Katner, D. L. Nelson et al., “Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder,” Neuropsychopharmacology, vol. 27, no. 5, pp. 699–711, 2002. View at Publisher · View at Google Scholar · View at Scopus
  340. D. T. Wong, P. G. Threlkeld, K. L. Best, and F. P. Bymaster, “A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain,” Journal of Pharmacology and Experimental Therapeutics, vol. 222, no. 1, pp. 61–65, 1982. View at Google Scholar · View at Scopus
  341. B. K. Madras, Z. Xie, Z. Lin et al., “Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 561–569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  342. S. Singh, “Chemistry, design, and structure-activity relationship of cocaine antagonists,” Chemical Reviews, vol. 100, no. 3, pp. 925–1024, 2000. View at Publisher · View at Google Scholar · View at Scopus
  343. S. Cheetham, S. Butler, M. Hearson et al., “BTS 74 398: a novel monoamine reuptake inhibitor for the treatment of Parkinson's disease,” The British Journal of Pharmacology, vol. 123, supplement 1, article 224P, 1998. View at Google Scholar
  344. P. H. Andersen, “The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action,” European Journal of Pharmacology, vol. 166, no. 3, pp. 493–504, 1989. View at Publisher · View at Google Scholar · View at Scopus
  345. J.-M. Owens, D. L. Knight, and C. B. Nemeroff, “Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine,” Encephale, vol. 28, no. 4, pp. 350–355, 2002. View at Google Scholar · View at Scopus
  346. D. T. Wong, J. S. Horng, F. P. Bymaster, K. L. Hauser, and B. B. Molloy, “A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine,” Life Sciences, vol. 15, no. 3, pp. 471–479, 1974. View at Publisher · View at Google Scholar · View at Scopus
  347. R. B. Rothman, M. H. Baumann, C. M. Dersch et al., “Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin,” Synapse, vol. 39, no. 1, pp. 32–41, 2001. View at Google Scholar
  348. G. Gianutsos, G. Morrow, S. Light, and M. J. Sweeney, “Dopaminergic properties of nomifensine,” Pharmacology Biochemistry and Behavior, vol. 17, no. 5, pp. 951–954, 1982. View at Publisher · View at Google Scholar · View at Scopus
  349. M. Hajós, J. C. Fleishaker, J. K. Filipiak-Reisner, M. T. Brown, and E. H. F. Wong, “The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile,” CNS Drug Reviews, vol. 10, no. 1, pp. 23–44, 2004. View at Google Scholar · View at Scopus
  350. C. D. Verrico, G. M. Miller, and B. K. Madras, “MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: Implications for MDMA-induced neurotoxicity and treatment,” Psychopharmacology, vol. 189, no. 4, pp. 489–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  351. D. T. Wong, F. P. Bymaster, D. A. Mayle, L. R. Reid, J. H. Krushinski, and D. W. Robertson, “LY248686, a new inhibitor of serotonin and norepinephrine uptake,” Neuropsychopharmacology, vol. 8, no. 1, pp. 23–33, 1993. View at Publisher · View at Google Scholar · View at Scopus
  352. G. Battaglia, B. P. Brooks, C. Kulsakdinun, and E. B. De Souza, “Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites,” European Journal of Pharmacology, vol. 149, no. 1-2, pp. 159–163, 1988. View at Publisher · View at Google Scholar · View at Scopus
  353. P. Huot, T. H. Johnston, K. D. Lewis et al., “Effects of R- and S-MDMA on L-DOPA-induced dyskinesia and duration of on-time in the MPTP-lesioned common marmoset,” Society for Neuroscience, 2010.
  354. R. B. Rothman, J. S. Partilla, M. H. Baumann, C. M. Dersch, F. I. Carroll, and K. C. Rice, “Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse,” Synapse, vol. 35, no. 3, pp. 222–227, 2000. View at Publisher · View at Google Scholar
  355. C. Moret, M. Charveron, J. P. M. Finberg, J. P. Couzinier, and M. Briley, “Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug,” Neuropharmacology, vol. 24, no. 12, pp. 1211–1219, 1985. View at Publisher · View at Google Scholar · View at Scopus
  356. T. H. de Boer, G. Maura, M. Raiteri, C. J. de Vos, J. Wieringa, and R. M. Pinder, “Neurochemical and autonomic pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers,” Neuropharmacology, vol. 27, no. 4, pp. 399–408, 1988. View at Publisher · View at Google Scholar · View at Scopus
  357. M. J. Minzenberg and C. S. Carter, “Modafinil: a review of neurochemical actions and effects on cognition,” Neuropsychopharmacology, vol. 33, no. 7, pp. 1477–1502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  358. E. Mignot, S. Nishino, C. Guilleminault, and W. C. Dement, “Modafinil binds to the dopamine uptake carrier site with low affinity,” Sleep, vol. 17, no. 5, pp. 436–437, 1994. View at Google Scholar · View at Scopus
  359. S. C. Cheetham, J. A. Viggers, S. A. Butler, M. R. Prow, and D. J. Heal, “[3H]nisoxetine—a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments,” Neuropharmacology, vol. 35, no. 1, pp. 63–70, 1996. View at Publisher · View at Google Scholar · View at Scopus
  360. D. T. Wong, J. S. Horng, and F. P. Bymaster, “dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart,” Life Sciences, vol. 17, no. 5, pp. 755–760, 1975. View at Publisher · View at Google Scholar · View at Scopus
  361. M. L. Bondarev, T. S. Bondareva, R. Young, and R. A. Glennon, “Behavioral and biochemical investigations of bupropion metabolites,” European Journal of Pharmacology, vol. 474, no. 1, pp. 85–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  362. M. I. Damaj, F. I. Carroll, J. B. Eaton et al., “Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors,” Molecular Pharmacology, vol. 66, no. 3, pp. 675–682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  363. T. H. Johnston, S. H. Fox, J. Ma et al., “SEP-228791, a novel dopamine and norepinephrine re-uptake inhibitor, has anti-parkinsonian actions, without eliciting dyskinesia, in the MPTP-lesioned primate model of Parkinson's disease,” Neurology, vol. 74, supplement 2, article A360, 2010. View at Google Scholar
  364. D. M. Marks, C. U. Pae, and A. A. Patkar, “Triple reuptake inhibitors: the next generation of antidepressants,” Current Neuropharmacology, vol. 6, no. 4, pp. 338–343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  365. G. Jorgen Scheel-Kruger, P. Moldt, and F. Watjen, “Tropane-derivatives, their preparation and use,” US Patent 6,395,748, 2002.
  366. G. Kato and A. F. Weitsch, “Neurochemical profile of tianeptine, a new antidepressant drug,” Clinical Neuropharmacology, vol. 11, supplement 2, pp. S43–S50, 1988. View at Google Scholar · View at Scopus
  367. T. H. Johnston, P. Huot, S. H. Fox, M. J. Piggott, and J. M. Brotchie, “The ability of UWA-0101 to enhance anti-parkinsonian actions of L-DOPA in the MPTP-lesioned primate may result from mixed, though selective, inhibition of dopamine and serotonin re-uptake,” Movement Disorders, vol. 24, supplement 1, p. S353, 2009. View at Google Scholar
  368. P. Huot, T. H. Johnston, M. G. Reyes, K. D. Lewis, S. H. Fox, and M. J. Piggott, “A novel mixed monoamine uptake inhibitor, UWA-0121, increases quality and duration of L-DOPA action in the MPTP-lesioned primate model of Parkinson's disease,” Society for Neuroscience, 2009.
  369. P. Huot, T. H. Johnston, M. G. Reyes et al., “UWA-0121, a novel dopamine and serotonin re-uptake inhibitor, increases quality and duration of L-DOPA anti-parkinsonian actions in the MPTP-lesioned primate model of Parkinson's disease,” Neurology, vol. 74, supplement 2, article A394, 2010. View at Google Scholar
  370. R. E. Heikkila and L. Manzino, “Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake,” European Journal of Pharmacology, vol. 103, no. 3-4, pp. 241–248, 1984. View at Publisher · View at Google Scholar · View at Scopus
  371. L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth, “Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor,” The Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 1, pp. 83–89, 2001. View at Google Scholar · View at Scopus
  372. L. L. Werling, A. Keller, J. G. Frank, and S. J. Nuwayhid, “A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder,” Experimental Neurology, vol. 207, no. 2, pp. 248–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  373. E. Schraven and R. Reibert, “Inhibition of monoamine oxidase A and B of rat heart and brain by amitriptyline, pargyline and pirlindole,” Drug Research, vol. 34, no. 10, pp. 1258–1260, 1984. View at Google Scholar · View at Scopus
  374. A. N. Cokugras and E. F. Tezcan, “Amitriptyline: a potent inhibitor of butyrylcholinesterase from human serum,” General Pharmacology, vol. 29, no. 5, pp. 835–838, 1997. View at Publisher · View at Google Scholar · View at Scopus
  375. M. A. Sills and P. S. Loo, “Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate,” Molecular Pharmacology, vol. 36, no. 1, pp. 160–165, 1989. View at Google Scholar · View at Scopus
  376. M. A. Punke and P. Friederich, “Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels,” Anesthesia and Analgesia, vol. 104, no. 5, pp. 1256–1264, 2007. View at Publisher · View at Google Scholar · View at Scopus
  377. J. J. Pancrazio, G. L. Kamatchi, A. K. Roscoe, and C. Lynch III, “Inhibition of neuronal Na+ channels by antidepressant drugs,” The Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 208–214, 1998. View at Google Scholar · View at Scopus
  378. I. Zahradník, I. Minarovič, and A. Zahradníková, “Inhibition of the cardiac L-type calcium channel current by antidepressant drugs,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 977–984, 2008. View at Publisher · View at Google Scholar
  379. S.-W. Jang, X. Liu, C.-B. Chan et al., “Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity,” Chemistry and Biology, vol. 16, no. 6, pp. 644–656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  380. K. L. Paumier, C. E. Sortwell, B. F. Daley et al., “Tricyclic antidepressant treatment protects dopamine neurons and increases neurotrophic factors within the nigrostriatal system,” Tech. Rep. Program no. 45.13/E34, Society for Neuroscience, Chicago, Ill, USA, 2009. View at Google Scholar
  381. K. L. Paumier, C. E. Sortwell, B. F. Daley et al., “Chronic antidepressant treatment is neuroprotective in a rat model of Parkinson's disease,” Movement Disorders, vol. 23, supplement 1, pp. S316–S317, 2008. View at Google Scholar
  382. M. Kawajiri, Y. Ohyagi, H. Furuya et al., “A patient with Parkinson's disease complicated by hypothyroidism who developed malignant syndrome after discontinuation of etizolam,” Clinical Neurology, vol. 42, no. 2, pp. 136–139, 2002. View at Google Scholar · View at Scopus
  383. R. Sandyk, “Serotonergic mechanisms in levodopa-induced ‘on-off’ and sleep disorders in Parkinson's disease,” International Journal of Neuroscience, vol. 43, no. 3-4, pp. 207–213, 1988. View at Publisher · View at Google Scholar · View at Scopus
  384. R. Sandyk, R. P. Iacono, and C. R. Bamford, “Spinal cord mechanisms in amitriptyline responsive restless legs syndrome in Parkinson's disease,” International Journal of Neuroscience, vol. 38, no. 1-2, pp. 121–124, 1988. View at Publisher · View at Google Scholar · View at Scopus
  385. D. S. Rampton, “Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline,” British Medical Journal, vol. 2, no. 6087, pp. 607–608, 1977. View at Publisher · View at Google Scholar · View at Scopus
  386. M. Edwards, “Adverse interaction of levodopa with tricyclic antidepressants,” The Practitioner, vol. 226, no. 1370, pp. 1447–1449, 1982. View at Google Scholar · View at Scopus
  387. W. Knopp, “Psychiatric changes in patients treated with levodopa. I. The clinical experiment,” Neurology, vol. 20, no. 12, pp. 23–30, 1970. View at Google Scholar · View at Scopus
  388. W. Knopp, “Psychiatric changes in patients treated with levodopa. I. The clinical experiment,” Neurology, vol. 20, supplement, no. 12, pp. 23–30, 1970. View at Google Scholar · View at Scopus
  389. A. M. Wagshul and R. B. Daroff, “Depression during L-dopa treatment,” The Lancet, vol. 2, no. 7620, p. 592, 1969. View at Google Scholar · View at Scopus
  390. A. Indaco and P. B. Carrieri, “Amitriptyline in the treatment of headache in patients with Parkinson's disease: a double-blind placebo-controlled study,” Neurology, vol. 38, no. 11, pp. 1720–1722, 1988. View at Publisher · View at Google Scholar · View at Scopus
  391. M. Serrano-Dueñas, “A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease,” Revista de Neurologia, vol. 35, no. 11, pp. 1010–1014, 2002. View at Google Scholar · View at Scopus
  392. J. M. Rabey, E. Orlov, and A. D. Korczyn, “Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease,” Neurology, vol. 46, p. A374, 1996. View at Google Scholar
  393. J. M. Miyasaki, K. Shannon, V. Voon et al., “Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 66, no. 7, pp. 996–1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  394. B. E. Roos, “Parkinson's syndrome. 10. Effects of psychopharmacological agents on central monoamine neurons,” Lakartidningen, vol. 67, no. 42, pp. 4840–4841, 1970. View at Google Scholar · View at Scopus
  395. F. Braasch, “Therapy of agitated depression using Saroten retard 75 and psychopathologic reflexions on the disease,” Nervenarzt, vol. 42, no. 12, pp. 645–650, 1971. View at Google Scholar · View at Scopus
  396. H. Takahashi, M. Kamata, K. Yoshida, H. Higuchi, and T. Shimizu, “Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 29, no. 2, pp. 351–353, 2005. View at Publisher · View at Google Scholar · View at Scopus
  397. T. Maruyama, “New treatment of depression in Parkinson's disease,” International Journal of Psychiatry in Clinical Practice, vol. 7, supplement 1, pp. 25–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  398. E. Richelson and A. Nelson, “Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 230, no. 1, pp. 94–102, 1984. View at Google Scholar · View at Scopus
  399. P. S. Driver, “Depression treatment in Parkinson's disease,” DICP: The Annals of Pharmacotherapy, vol. 25, no. 2, pp. 137–138, 1991. View at Google Scholar · View at Scopus
  400. F. Jenck, J.-L. Moreau, V. Mutel, and J. R. Martin, “Brain 5-HT1C receptors and antidepressants,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 18, no. 3, pp. 563–574, 1994. View at Publisher · View at Google Scholar · View at Scopus
  401. D. S. Sa, S. Kapur, and A. E. Lang, “Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis,” Clinical Neuropharmacology, vol. 24, no. 4, pp. 242–244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  402. J. Sharkey, K. A. Glen, S. Wolfe, and M. J. Kuhar, “Cocaine binding at σ receptors,” European Journal of Pharmacology, vol. 149, no. 1-2, pp. 171–174, 1988. View at Publisher · View at Google Scholar · View at Scopus
  403. J. Sharkey, M. C. Ritz, J. A. Schenden, R. C. Hanson, and M. J. Kuhar, “Cocaine inhibits muscarinic cholinergic receptors in heart and brain,” The Journal of Pharmacology and Experimental Therapeutics, vol. 246, no. 3, pp. 1048–1052, 1988. View at Google Scholar · View at Scopus
  404. E. C. Nguyen, K. A. McCracken, Y. Liu, B. Pouw, and R. R. Matsumoto, “Involvement of sigma (σ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies,” Neuropharmacology, vol. 49, no. 5, pp. 638–645, 2005. View at Publisher · View at Google Scholar · View at Scopus
  405. R. T. Stormont, “NEW and nonofficial remedies: propylhexedrine,” The Journal of the American Medical Association, vol. 150, no. 12, article 1220, 1952. View at Google Scholar
  406. D. R. Wesson, “Propylhexdrine,” Drug and Alcohol Dependence, vol. 17, no. 2-3, pp. 273–278, 1986. View at Publisher · View at Google Scholar · View at Scopus
  407. G. A. Ricaurte, A. O. Mechan, J. Yuan et al., “Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 1, pp. 91–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  408. W. L. Woolverton, G. A. Ricaurte, L. S. Forno, and L. S. Seiden, “Long-term effects of chronic methamphetamine administration in rhesus monkeys,” Brain Research, vol. 486, no. 1, pp. 73–78, 1989. View at Publisher · View at Google Scholar · View at Scopus
  409. K. L. Preston, G. C. Wagner, C. R. Schuster, and L. S. Seiden, “Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain,” Brain Research, vol. 338, no. 2, pp. 243–248, 1985. View at Publisher · View at Google Scholar · View at Scopus
  410. V. Villemagne, J. Yuan, D. F. Wong et al., “Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations,” Journal of Neuroscience, vol. 18, no. 1, pp. 419–427, 1998. View at Google Scholar · View at Scopus
  411. B. A. Morrow, R. H. Roth, D. E. Redmond, and J. D. Elsworth, “Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease,” Neuroscience, vol. 189, pp. 277–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  412. D. C. Harvey, G. Lacan, S. P. Tanious, and W. P. Melega, “Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss,” Brain Research, vol. 871, no. 2, pp. 259–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  413. D. C. Harvey, G. Laćan, and W. P. Melega, “Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure,” Experimental Brain Research, vol. 133, no. 3, pp. 349–358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  414. S. Ares-Santos, N. Granado, I. Espadas, R. Martinez-Murillo, and R. Moratalla, “Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining,” Neuropsychopharmacology, vol. 39, no. 5, pp. 1066–1080, 2014. View at Publisher · View at Google Scholar · View at Scopus
  415. G. Natale, O. Kastsiuchenka, L. Pasquali, S. Ruggieri, A. Paparelli, and F. Fornai, “MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut,” Annals of the New York Academy of Sciences, vol. 1139, pp. 345–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  416. R. Ruffoli, M. A. Giambelluca, M. C. Scavuzzo, L. Pasquali, F. Giannessi, and F. Fornai, “MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss,” Brain Research, vol. 1229, pp. 218–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  417. U. D. McCann, D. F. Wong, F. Yokoi, V. Villemagne, R. F. Dannals, and G. A. Ricaurte, “Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428,” The Journal of Neuroscience, vol. 18, no. 20, pp. 8417–8422, 1998. View at Google Scholar · View at Scopus
  418. U. D. McCann, H. Kuwabara, A. Kumar et al., “Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users,” Synapse, vol. 62, no. 2, pp. 91–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  419. J. M. Wilson, K. S. Kalasinsky, A. I. Levey et al., “Striatal dopamine nerve terminal markers in human, chronic methamphetamine users,” Nature Medicine, vol. 2, no. 6, pp. 699–703, 1996. View at Publisher · View at Google Scholar · View at Scopus
  420. R. C. Callaghan, J. K. Cunningham, G. Sajeev, and S. J. Kish, “Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders,” Movement Disorders, vol. 25, no. 14, pp. 2333–2339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  421. R. C. Callaghan, J. Sykes, L. Taylor, M. Verdichevski, and S. J. Kish, “Are individuals with methamphetamine-use disorders at higher than normal risk for developing Parkinson’s disease?” Movement Disorders, vol. 26, supplement 2, p. S50, 2011. View at Google Scholar
  422. R. C. Callaghan, J. K. Cunningham, J. Sykes, and S. J. Kish, “Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs,” Drug and Alcohol Dependence, vol. 120, no. 1–3, pp. 35–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  423. E. R. Garwood, W. Bekele, C. E. McCulloch, and C. W. Christine, “Amphetamine exposure is elevated in Parkinson's disease,” NeuroToxicology, vol. 27, no. 6, pp. 1003–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  424. S. van den Eeden, C. M. Tanner, K. S. Albers et al., “Amphetamine use and risk of Parkinson's disease in a prospective study,” Neurology, vol. 76, supplement 4, article A362, 2011. View at Google Scholar
  425. G. Todd, C. Noyes, S. C. Flavel et al., “Illicit stimulant use is associated with abnormal substantia nigra morphology in humans,” PLoS ONE, vol. 8, no. 2, Article ID e56438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  426. C. W. Christine, E. R. Garwood, L. E. Schrock, D. E. Austin, and C. E. McCulloch, “Parkinsonism in patients with a history of amphetamine exposure,” Movement Disorders, vol. 25, no. 2, pp. 228–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  427. C. W. Christine, L. E. Schrock, D. Austin, and E. R. Garwood, “Parkinsonian phenotype in patients with prior exposure to amphetamine,” Movement Disorders, vol. 23, supplement 1, p. S274, 2008. View at Google Scholar
  428. P. Nowak, G. Szczerbak, I. Biedka, M. Drosik, R. M. Kostrzewa, and R. Brus, “Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in parkinsonian rats. In vivo microdialysis study,” Journal of Physiology and Pharmacology, vol. 57, no. 4, pp. 583–597, 2006. View at Google Scholar · View at Scopus
  429. M. Olsson, G. Nikkhah, C. Bentlage, and A. Bjorklund, “Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test,” Journal of Neuroscience, vol. 15, no. 5, pp. 3863–3875, 1995. View at Google Scholar · View at Scopus
  430. U. Ungerstedt, “Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour,” Acta Physiologica Scandinavica, Supplement, vol. 367, pp. 49–68, 1971. View at Google Scholar · View at Scopus
  431. H. A. Robertson, M. R. Peterson, K. Murphy, and G. S. Robertson, “D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour,” Brain Research, vol. 503, no. 2, pp. 346–349, 1989. View at Publisher · View at Google Scholar · View at Scopus
  432. J. L. Hudson, C. G. van Horne, I. Stromberg et al., “Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats,” Brain Research, vol. 626, no. 1-2, pp. 167–174, 1993. View at Publisher · View at Google Scholar · View at Scopus
  433. L. S. Carman, F. H. Gage, and C. W. Shults, “Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior,” Brain Research, vol. 553, no. 2, pp. 275–283, 1991. View at Publisher · View at Google Scholar · View at Scopus
  434. T. Lee, P. Seeman, A. Rajput, I. J. Farley, and O. Hornykiewicz, “Receptor basis for dopaminergic supersensitivity in Parkinson's disease,” Nature, vol. 273, no. 5657, pp. 59–61, 1978. View at Publisher · View at Google Scholar · View at Scopus
  435. C. Marin, M. C. Rodriguez-Oroz, and J. A. Obeso, “Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?” Experimental Neurology, vol. 197, no. 2, pp. 269–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  436. G. A. Smith, A. Heuer, A. Klein, N.-N. Vinh, S. B. Dunnett, and E. L. Lane, “Amphetamine-induced dyskinesia in the transplanted hemi-parkinsonian mouse,” Journal of Parkinson's Disease, vol. 2, no. 2, pp. 107–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  437. E. L. Lane, P. Brundin, and M. A. Cenci, “Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease,” Neurobiology of Disease, vol. 35, no. 1, pp. 42–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  438. G. A. Smith, L. S. Breger, E. L. Lane, and S. B. Dunnett, “Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats,” Neuropharmacology, vol. 63, no. 5, pp. 818–828, 2012. View at Publisher · View at Google Scholar · View at Scopus
  439. E. L. Lane, L. Vercammen, M. A. Cenci, and P. Brundin, “Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats,” Experimental Neurology, vol. 219, no. 1, pp. 355–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  440. E. L. Lane, D. Soulet, L. Vercammen, M. A. Cenci, and P. Brundin, “Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease,” Neurobiology of Disease, vol. 32, no. 2, pp. 220–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  441. K. E. Soderstrom, G. Meredith, T. B. Freeman et al., “The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors,” Neurobiology of Disease, vol. 32, no. 2, pp. 229–242, 2008. View at Publisher · View at Google Scholar · View at Scopus
  442. E. Shin, C. Lisci, E. Tronci et al., “The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation,” Neurobiology of Disease, vol. 62, pp. 233–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  443. J. García, T. Carlsson, M. Döbrössy, G. Nikkhah, and C. Winkler, “Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model,” Brain Research, vol. 1470, pp. 119–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  444. J. L. Riddle, S. L. Rokosik, and T. C. Napier, “Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls,” Behavioural Brain Research, vol. 233, no. 1, pp. 15–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  445. Y. Ishida, K. Kawai, Y. Magata et al., “Differential expression of fos and Zif268 in the nigrostriatal system after methamphetamine administration in a rat model of Parkinson's disease,” Synapse, vol. 62, no. 12, pp. 920–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  446. Y. Ishida, K. Todaka, I. Kuwahara et al., “Methamphetamine-induced Fos expression in the substantia nigra pars reticulata in rats with a unilateral 6-OHDA lesion of the nigrostriatal fibers,” Neuroscience Research, vol. 30, no. 4, pp. 355–360, 1998. View at Publisher · View at Google Scholar · View at Scopus
  447. Y. Ishida, K. Todaka, I. Kuwahara et al., “Methamphetamine induces Fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease,” Brain Research, vol. 809, no. 1, pp. 107–114, 1998. View at Publisher · View at Google Scholar · View at Scopus
  448. J. M. Henderson, D. Stanic, D. Tomas et al., “Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys,” Behavioural Brain Research, vol. 160, no. 2, pp. 267–276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  449. J. M. Henderson, L. E. Annett, E. M. Torres, and S. B. Dunnett, “Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus),” European Journal of Neuroscience, vol. 10, no. 2, pp. 689–698, 1998. View at Publisher · View at Google Scholar · View at Scopus
  450. L. E. Annett, E. M. Torres, D. J. Clarke et al., “Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age,” Cell Transplantation, vol. 6, no. 6, pp. 557–569, 1997. View at Publisher · View at Google Scholar · View at Scopus
  451. L. E. Annett, F. L. Martel, D. C. Rogers, R. M. Ridley, H. F. Baker, and S. B. Dunnett, “Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway,” Experimental Neurology, vol. 125, no. 2, pp. 228–246, 1994. View at Publisher · View at Google Scholar · View at Scopus
  452. S. Chen, “Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys,” Chinese Journal of Neurology and Psychiatry, vol. 25, no. 1, pp. 50–64, 1992. View at Google Scholar · View at Scopus
  453. J. Yanai, W. F. Silverman, and D. Shamir, “An avian model for the reversal of 6-hydroxydopamine induced rotating behaviour by neural grafting,” Neuroscience Letters, vol. 187, no. 3, pp. 153–156, 1995. View at Publisher · View at Google Scholar · View at Scopus
  454. D. S. Baskin, J. L. Browning, M. A. Widmayer, Z.-Q. Zhu, and R. G. Grossman, “Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion,” Life Sciences, vol. 54, no. 7, pp. 471–479, 1994. View at Publisher · View at Google Scholar · View at Scopus
  455. J. L. Cadet, C. Brannock, B. Ladenheim, M. T. McCoy, J. Chou, and E. Lehrmann, “Transcriptome profiling in 6-hydroxydopamine hemiparkinsonian rats reveals methamphetamine-mediated dopamine-independant changes in striatal gene expression [Abstract],” Social Neuroscience, 2010. View at Google Scholar
  456. J. L. Cadet, C. Brannock, I. N. Krasnova et al., “Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6- hydroxydopamine hemiparkinsonian rats,” PLoS ONE, vol. 5, no. 12, Article ID e15643, 2010. View at Publisher · View at Google Scholar · View at Scopus
  457. J. L. Cadet, C. Brannock, B. Ladenheim, M. T. McCoy, J. Chou, and E. Lehrmann, “Transcriptome profiling in 6-hydroxydopamine hemiparkinsonian rats revealed methamphetamine-mediated dopamine-independant changes in striatal gene expression,” Society for Neuroscience 69.10/II9, 2011. View at Google Scholar
  458. B. D. West, P. J. Shughrue, A. E. H. Vanko, R. W. Ransom, and G. G. Kinney, “Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment,” Pharmacology Biochemistry and Behavior, vol. 84, no. 1, pp. 158–161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  459. C. H. Cashin and S. Sutton, “The effect of anti-Parkinson drugs on catalepsy induced by α-methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine,” British Journal of Pharmacology, vol. 47, no. 3, pp. 658P–659P, 1973. View at Google Scholar · View at Scopus
  460. P. Piccini, N. Pavese, and D. J. Brooks, “Endogenous dopamine release after pharmacological challenges in Parkinson's disease,” Annals of Neurology, vol. 53, no. 5, pp. 647–653, 2003. View at Publisher · View at Google Scholar · View at Scopus
  461. M. Politis, K. Wu, C. Loane et al., “Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts,” Science Translational Medicine, vol. 4, Article ID 128ra41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  462. R. Nandhagopal, M. J. McKeown, and A. J. Stoessl, “Functional imaging in Parkinson disease,” Neurology, vol. 70, no. 16, pp. 1478–1488, 2008. View at Publisher · View at Google Scholar · View at Scopus
  463. N. Pavese, O. Rimoldi, A. Gerhard, D. J. Brooks, and P. Piccini, “Cardiovascular effects of methamphetamine in Parkinson's disease patients,” Movement Disorders, vol. 19, no. 3, pp. 298–303, 2004. View at Publisher · View at Google Scholar · View at Scopus
  464. P. Solomon, R. S. Mitchell, and M. Prinzmetal, “The use of benzedrine sulfate in postencephalitic Parkinson's disease,” The Journal of the American Medical Association, vol. 108, no. 21, pp. 1765–1770, 1937. View at Publisher · View at Google Scholar
  465. R. A. Matthews, “Symptomatic treatment of chronic encephalitis with benzedrine sulphate,” The American Journal of the Medical Sciences, vol. 195, pp. 448–451, 1938. View at Publisher · View at Google Scholar
  466. I. Finkelman and L. B. Shapiro, “Benzedrine sulfate and atropine in treatment of chronic encephalitis,” The Journal of the American Medical Association, vol. 109, no. 5, pp. 344–346, 1937. View at Publisher · View at Google Scholar
  467. R. S. Schwab and A. C. England Jr., “Problems in the treatment of Parkinsonism by analeptics,” Transactions of the American Neurological Association, pp. 51–57, 1956. View at Google Scholar · View at Scopus
  468. P. L. Davis and W. B. Stewart, “The use of benzedrine sulfate in postencephalitic parkinsonism,” The Journal of the American Medical Association, vol. 110, no. 23, pp. 1890–1892, 1938. View at Publisher · View at Google Scholar
  469. E. Miller and H. A. Nieburg, “Amphetamines, valuable adjunct in treatment of Parkinsonism,” New York State Journal of Medicine, vol. 73, no. 22, pp. 2657–2661, 1973. View at Google Scholar · View at Scopus
  470. P. A. Bhaskar, E. A. Bhaskar, and K. Jagannathan, “Augmenting procedures during L-dopa therapy for Parkinsonism.,” The Journal of the Association of Physicians of India, vol. 23, no. 1, pp. 21–27, 1975. View at Google Scholar · View at Scopus
  471. J. D. Parkes, D. Tarsy, C. D. Marsden et al., “Amphetamines in the treatmentof Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 38, no. 3, pp. 232–237, 1975. View at Publisher · View at Google Scholar · View at Scopus
  472. W. Umbach and D. Baumann, “The efficacy of L-dopa in Parkinson patients with and without stereotactic brain surgery,” Archiv für Psychiatrie und Nervenkrankheiten, vol. 205, no. 3, pp. 281–292, 1964. View at Google Scholar
  473. W. Birkmayer and E. Neumayer, “Modern treatment of parkinsonism,” Zeitschrift für Neurologie, vol. 202, no. 4, pp. 257–280, 1972. View at Publisher · View at Google Scholar · View at Scopus
  474. W. Umbach, “Different effects of drugs before and after stereotaxic operation,” Confinia Neurologica, vol. 27, no. 1, pp. 258–261, 1966. View at Publisher · View at Google Scholar · View at Scopus
  475. W. Umbach and O. Tzavellas, “On the treatment of akinetic symptoms in Parkinson's syndrome,” Deutsche Medizinische Wochenschrift, vol. 90, no. 44, pp. 1941–1944, 1965. View at Publisher · View at Google Scholar · View at Scopus
  476. W. Umbach and J. Woywode, “The effect of a substance of the amphetamine group in Parkinson's syndrome with prevalent akinesia. Clinical experiences and controls of action of cyclohexyl-isopropyl-methylamine HCl,” Medizinische Welt, vol. 41, pp. 2329–2336, 1965. View at Google Scholar · View at Scopus
  477. W. Birkmayer, “Conservative therapy in the Parkinson syndrome,” Wiener Medizinische Wochenschrift, vol. 121, no. 46, pp. 827–829, 1971. View at Google Scholar · View at Scopus
  478. J. S. Lou, D. Dimitrova, K. A. Chung, S. B. Andrea, and J. Nutt, “The effects of rivastigmine and atomoxetine on attention in non-demented Parkinson's disease (PD),” Movement Disorders, vol. 28, supplement 1, pp. S191–S192, 2013. View at Google Scholar
  479. G. J. Revuelta, A. J. Delambo, A. Embry, C. Gregory, J. Elm, and V. K. Hinson, “Atomoxetine for the treatment of non-levodopa responsive freezing of gait,” Movement Disorders, vol. 29, supplement 1, pp. S260–S261, 2014. View at Google Scholar
  480. C. Housden, A. A. Kehagia, R. A. Barker et al., “Effects of the noradrenaline reuptake blocker atomoxetine on impulsivity in Parkinson's disease [Abstract],” Society for Neuroscience, 2012.
  481. Z. Ye, E. Altena, C. Nombela et al., “Improving response inhibition in Parkinson's disease with atomoxetine,” Biological Psychiatry, 2014. View at Publisher · View at Google Scholar · View at Scopus
  482. A. A. Kehagia, C. R. Housden, R. Regenthal et al., “Targeting impulsivity in Parkinson's disease using atomoxetine (LBA 28),” Late-Breaking Abstracts and MDS Study Group Abstract Publication, 2014, http://www.mdscongress2014.org/abstractpublication.htm.
  483. L. Marsh, K. Biglan, M. Gerstenhaber, and J. R. Williams, “Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study,” Movement Disorders, vol. 24, no. 2, pp. 277–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  484. J. Jankovic, “Atomoxetine for freezing of gait in Parkinson disease,” Journal of the Neurological Sciences, vol. 284, no. 1-2, pp. 177–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  485. M. M. Nashatizadeh, J. E. Jimenez, A. L. Davidson, and J. Jankovic, “A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease,” Movement Disorders, vol. 23, supplement 1, p. S219, 2008. View at Google Scholar
  486. D. Weintraub, S. Mavandadi, S. Horn et al., “Atomoxetine for the treatment of depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study,” Movement Disorders, vol. 24, supplement 1, p. S286, 2009. View at Google Scholar
  487. D. Weintraub, S. Mavandadi, E. Mamikonyan et al., “Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease,” Neurology, vol. 75, no. 5, pp. 448–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  488. NCT01316666, http://www.clinicaltrials.gov/.
  489. NCT00286949, http://www.clinicaltrials.gov/.
  490. NCT01738191, http://www.clinicaltrials.gov/.
  491. J. L. Waddington, “Effects of nomifensine and desipramine on the sequelae of intracerebrally-injected 6-OHDA and 5,6-DHT,” Pharmacology Biochemistry and Behavior, vol. 13, no. 6, pp. 915–917, 1980. View at Publisher · View at Google Scholar · View at Scopus
  492. R. Cash, T. Dennis, R. L'Heureux, R. Raisman, F. Javoy-Agid, and B. Scatton, “Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus,” Neurology, vol. 37, no. 1, pp. 42–46, 1987. View at Publisher · View at Google Scholar · View at Scopus
  493. N. Matussek and H. Pohlmeier, “Wirkung von desmethylimipramin (Pertofran) auf den catecholamin-stoffwechsel im ZNS und auf das Parkinson-syndrom,” Klinische Wochenschrift, vol. 43, no. 14, pp. 797–798, 1965. View at Publisher · View at Google Scholar · View at Scopus
  494. H. Pohlmeier and N. Matussek, “Investigations on the effect of desmethylimipramine-Pertofran on parkinsonism in man,” Archiv für Psychiatrie und Nervenkrankheiten, vol. 207, no. 3, pp. 174–184, 1965. View at Google Scholar
  495. L. Laitinen, “Desipramine in treatment of Parkinson's disease. A placebo-controlled study,” Acta Neurologica Scandinavica, vol. 45, no. 1, pp. 109–113, 1969. View at Publisher · View at Google Scholar · View at Scopus
  496. E. de Divitiis, C. D. Signorelli, and A. Cerillo, “Desipramine in the therapy of Parkinson's disease,” Rassegna Internazionale di Clinica e Terapia, vol. 51, no. 4, pp. 222–226, 1971. View at Google Scholar · View at Scopus
  497. G. B. Muscettola, M. Giovannucci, R. Montanini, P. L. Morselli, and S. Garattini, “Relationship between desipramine plasma levels and the effect in Parkinson's syndrome,” Revue Europeenne d"Etudes Cliniques et Biologiques, vol. 17, no. 4, pp. 375–379, 1972. View at Google Scholar · View at Scopus
  498. F. Geissbuhler, G. Bartholini, J. M. Gaillard, and R. Tissot, “Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes,” Encephale, vol. 60, no. 3, pp. 189–209, 1971. View at Google Scholar · View at Scopus
  499. R. Sandyk, “Maprotiline for disordered cognitive function in Parkinson's disease,” Clinical Pharmacy, vol. 5, no. 1, pp. 16–23, 1986. View at Google Scholar · View at Scopus
  500. H. Lefebvre, C. Noblet, N. Moore, and L. M. Wolf, “Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline,” Clinical Endocrinology, vol. 42, no. 1, pp. 95–99, 1995. View at Publisher · View at Google Scholar · View at Scopus
  501. S. Baykoushev and V. Temenlieva, “Ludiomil in parkinsonism (EMG and clinical study),” Folia Medica (Plovdiv), vol. 29, no. 4, pp. 5–6, 1987. View at Google Scholar · View at Scopus
  502. S. Baykoushev, E. Hadjipetrova, and V. Temenlieva, “Ludiomil in the treatment of parkinsonism,” Folia Medica, vol. 31, no. 2, pp. 7–9, 1989. View at Google Scholar · View at Scopus
  503. W. J. Houlihan and L. Kelly, “Assessment of mazindane, a pro-drug form of mazindol, in assays used to define cocaine treatment agents,” European Journal of Pharmacology, vol. 458, no. 3, pp. 263–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  504. M. Porritt, D. Stanic, D. Finkelstein et al., “Dopaminergic innervation of the human striatum in Parkinson's disease,” Movement Disorders, vol. 20, no. 7, pp. 810–818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  505. M. A. Piggott, E. F. Marshall, N. Thomas et al., “Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution,” Brain, vol. 122, no. 8, pp. 1449–1468, 1999. View at Publisher · View at Google Scholar · View at Scopus
  506. G. Kunikowska and P. Jenner, “Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease,” Brain Research, vol. 968, no. 2, pp. 206–218, 2003. View at Publisher · View at Google Scholar · View at Scopus
  507. T. V. Wade and J. S. Schneider, “Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs,” Journal of Neuroscience, vol. 21, no. 13, pp. 4901–4907, 2001. View at Google Scholar · View at Scopus
  508. T. Araki, M. Matsubara, K. Fujihara, H. Kato, Y. Imai, and Y. Itoyama, “Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle,” Neurological Research, vol. 24, no. 1, pp. 107–112, 2002. View at Publisher · View at Google Scholar · View at Scopus
  509. P. J. Delwaide, P. Martinelli, and J. Schoenen, “Mazindol in the treatment of Parkinson's disease,” Archives of Neurology, vol. 40, no. 13, pp. 788–790, 1983. View at Publisher · View at Google Scholar · View at Scopus
  510. J. Fernández, J. M. Alonso, J. I. Andrés et al., “Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents,” Journal of Medicinal Chemistry, vol. 48, no. 6, pp. 1709–1712, 2005. View at Publisher · View at Google Scholar · View at Scopus
  511. A. R. Kooyman, R. Zwart, P. M. L. Vanderheijden, J. A. van Hooft, and H. P. M. Vijverberg, “Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells,” Neuropharmacology, vol. 33, no. 3-4, pp. 501–507, 1994. View at Publisher · View at Google Scholar · View at Scopus
  512. S. Neumane, S. Mounayar, C. Jan et al., “Effects of dopamine and serotonin antagonist injections into the striatopallidal complex of asymptomatic MPTP-treated monkeys,” Neurobiology of Disease, vol. 48, no. 1, pp. 27–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  513. G. Fénelon, F. Mahieux, R. Huon, and M. Ziégler, “Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors,” Brain, vol. 123, no. 4, pp. 733–745, 2000. View at Publisher · View at Google Scholar · View at Scopus
  514. K. Ikeguchi and A. Kuroda, “Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs,” European Archives of Psychiatry and Clinical Neuroscience, vol. 244, no. 6, pp. 320–324, 1995. View at Publisher · View at Google Scholar · View at Scopus
  515. K. Fujimoto, T. Kawakami, K. Ikeguchi, and I. Nakano, “Safety and efficacy of mianserine on psychosis in Parkinson's disease [Abstract],” Movement Disorders, vol. 23, supplement 1, p. s214, 2008. View at Google Scholar
  516. K.-I. Fujimoto, “Management of non-motor complications in Parkinson's disease,” Journal of Neurology, vol. 256, supplement 3, pp. S299–S305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  517. K. Fujimoto, S. Sayama, N. Shizuma, K. Ikeguchi, and I. Nakano, “Mianserin therapy for psychosis in parkinsonism,” Neurologia Medico-Chirurgica, vol. 53, pp. 274–281, 2000. View at Google Scholar
  518. S. A. K. Anttila and E. V. J. Leinonen, “A review of the pharmacological and clinical profile of mirtazapine,” CNS Drug Reviews, vol. 7, no. 3, pp. 249–264, 2001. View at Google Scholar · View at Scopus
  519. T. de Boer, “The pharmacologic profile of mirtazapine,” Journal of Clinical Psychiatry, vol. 57, supplement 4, pp. 19–25, 1996. View at Google Scholar · View at Scopus
  520. G. Meco, E. Fabrizio, S. Di Rezze, A. Alessandri, and L. Pratesi, “Mirtazapine in L-dopa-induced dyskinesias,” Clinical Neuropharmacology, vol. 26, no. 4, pp. 179–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  521. G. Meco, P. Stirpe, F. Edito et al., “Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study,” Journal of Neural Transmission, vol. 116, no. 7, pp. 881–884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  522. V. Pact and T. Giduz, “Mirtazapine treats resting tremor, essential tremor, and levodopa—induced dyskinesias,” Neurology, vol. 53, no. 5, article 1154, 1999. View at Google Scholar · View at Scopus
  523. P. H. Gordon, S. L. Pullman, E. D. Louis, S. J. Frucht, and S. Fahn, “Mirtazapine in Parkinsonian tremor,” Parkinsonism and Related Disorders, vol. 9, no. 2, pp. 125–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  524. F. Alarcon and G. Estrada, “Tratamiento con mirtazapina del tremblor en 20 pacientes con enfermedad de Parkinson,” in Proceedings of the 9th Ecuadorian Congress of Neurology, Quito, Ecuador, 1999.
  525. M. Onofrj, A. L. Luciano, A. Thomas, D. Iacono, and G. D'Andreamatteo, “Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism,” Neurology, vol. 60, no. 1, pp. 113–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  526. C. Normann, B. Hesslinger, S. Frauenknecht, M. Berger, and J. Walden, “Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine,” Pharmacopsychiatry, vol. 30, no. 6, pp. 263–265, 1997. View at Publisher · View at Google Scholar · View at Scopus
  527. T. Nagata, S. Shinagawa, K. Tagai, and K. Nakayama, “A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease,” International Psychogeriatrics, vol. 25, no. 7, pp. 1199–1201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  528. T. Nagata, S. Shinagawa, K. Tagai, and K. Nakayama, “A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease,” International Psychogeriatrics, vol. 25, no. 7, pp. 1199–1201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  529. J. A. Godschalx-Dekker and H. P. Siegers, “Reduction of Parkinsonism and psychosis with mirtazapine: a case report,” Pharmacopsychiatry, vol. 47, no. 3, pp. 81–83, 2014. View at Publisher · View at Google Scholar · View at Scopus
  530. K. Tagai, T. Nagata, S. Shinagawa, N. Tsuno, M. Ozone, and K. Nakayama, “Mirtazapine improves visual hallucinations in Parkinson's disease: a case report,” Psychogeriatrics, vol. 13, no. 2, pp. 103–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  531. P. K. Gillman, “Tricyclic antidepressant pharmacology and therapeutic drug interactions updated,” British Journal of Pharmacology, vol. 151, no. 6, pp. 737–748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  532. J. Andersen, E. Aabro, N. Gulmann, A. Hjelmsted, and H. E. Pedersen, “Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA,” Acta Neurologica Scandinavica, vol. 62, no. 4, pp. 210–219, 1980. View at Google Scholar · View at Scopus
  533. M. Menza, R. D. Dobkin, H. Marin et al., “A controlled trial of antidepressants in patients with Parkinson disease and depression,” Neurology, vol. 72, no. 10, pp. 886–892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  534. N. P. Hinds, C. E. M. Hillier, and C. M. Wiles, “Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism,” Journal of Neurology, vol. 247, no. 10, p. 811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  535. M. R. Lemke, “Effect of reboxetine on depression in Parkinson's disease patients,” Journal of Clinical Psychiatry, vol. 63, no. 4, pp. 300–304, 2002. View at Publisher · View at Google Scholar · View at Scopus
  536. L. Pintor, E. Baillès, F. Valldeoriola, E. Tolosa, M. J. Martí, and J. de Pablo, “Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode,” General Hospital Psychiatry, vol. 28, no. 1, pp. 59–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  537. R. Samanin, A. Jori, S. Bernasconi, E. Morpugo, and S. Garattini, “Biochemical and pharmacological studies on amineptine (S 1694) and (+)-amphetamine in the rat,” Journal of Pharmacy and Pharmacology, vol. 29, no. 9, pp. 555–558, 1977. View at Publisher · View at Google Scholar · View at Scopus
  538. S. Torun, M. Uysal, and G. Ozdemir, “Moclobemide vs. amineptine in depressed patients with Parkinson's disease,” European Journal of Neurology, vol. 2, p. 92, 1995. View at Google Scholar
  539. L. Ferraro, T. Antonelli, W. T. O'Connor, S. Tanganelli, F. A. Rambert, and K. Fuxe, “The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission,” Neuroscience Letters, vol. 253, no. 2, pp. 135–138, 1998. View at Publisher · View at Google Scholar · View at Scopus
  540. S. Tanganelli, K. Fuxe, L. Ferraro, A. M. Janson, and C. Bianchi, “Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 345, no. 4, pp. 461–465, 1992. View at Google Scholar · View at Scopus
  541. M. Touret, M. Sallanon-Moulin, C. Fages et al., “Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain,” Molecular Brain Research, vol. 26, no. 1-2, pp. 123–128, 1994. View at Publisher · View at Google Scholar · View at Scopus
  542. K. P. Garnock-Jones, S. Dhillon, and L. J. Scott, “Armodafinil,” CNS Drugs, vol. 23, no. 9, pp. 793–803, 2009. View at Publisher · View at Google Scholar · View at Scopus
  543. A. Ueki, L. Rosen, B. Andbjer et al., “Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat,” Experimental Brain Research, vol. 96, no. 1, pp. 89–99, 1993. View at Publisher · View at Google Scholar · View at Scopus
  544. K. Fuxe, A. M. Janson, L. Rosen et al., “Evidence for a protective action of the vigilance promoting drug Modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis,” Experimental Brain Research, vol. 88, no. 1, pp. 117–130, 1992. View at Publisher · View at Google Scholar · View at Scopus
  545. J. A. Aguirre, A. Cintra, J. Hillion et al., “A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse,” Neuroscience Letters, vol. 275, no. 3, pp. 215–218, 1999. View at Publisher · View at Google Scholar · View at Scopus
  546. Y.-L. Xiao, J.-M. Fu, Z. Dong et al., “Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Acta Pharmacologica Sinica, vol. 25, no. 3, pp. 301–305, 2004. View at Google Scholar · View at Scopus
  547. A. Ueki, L. Rosen, B. Andbjer et al., “The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway,” Experimental Brain Research, vol. 93, no. 2, pp. 259–270, 1993. View at Google Scholar · View at Scopus
  548. P. Jenner, B. Y. Zeng, L. A. Smith et al., “Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset,” Experimental Brain Research, vol. 133, no. 2, pp. 178–188, 2000. View at Publisher · View at Google Scholar · View at Scopus
  549. B.-Y. Zeng, L. A. Smith, R. K. B. Pearce et al., “Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets,” Neuroscience Letters, vol. 354, no. 1, pp. 6–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  550. S. A. M. van Vliet, R. A. P. Vanwersch, M. J. Jongsma, J. van der Gugten, B. Olivier, and I. H. C. H. M. Philippens, “Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects,” Behavioural Pharmacology, vol. 17, no. 5-6, pp. 453–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  551. S. A. M. van Vlieta, E. L. A. Blezer, M. J. Jongsma, R. A. P. Vanwersch, B. Olivier, and I. H. C. H. M. Philippens, “Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy,” Brain Research, vol. 1189, no. 1, pp. 219–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  552. S. A. M. van Vliet, R. A. P. Vanwersch, M. J. Jongsma, B. Olivier, and I. H. C. H. M. Philippens, “Therapeutic effects of Δ9-THC and modafinil in a marmoset Parkinson model,” European Neuropsychopharmacology, vol. 18, no. 5, pp. 383–389, 2008. View at Publisher · View at Google Scholar · View at Scopus
  553. A. Rabinstein, L. M. Shulman, and W. J. Weiner, “Modafinil for the treatment of excessive daytime sleepiness in Parkinson's disease: a case report,” Parkinsonism and Related Disorders, vol. 7, no. 4, pp. 287–288, 2001. View at Publisher · View at Google Scholar · View at Scopus
  554. R. A. Hauser, M. N. Wahba, T. A. Zesiewicz, and W. M. Anderson, “Modafinil treatment of pramipexole-associated somnolence,” Movement Disorders, vol. 15, no. 6, pp. 1269–1271, 2000. View at Publisher · View at Google Scholar
  555. S. Happe, W. Pirker, C. Sauter, G. Klösch, and J. Zeitlhofer, “Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil,” Journal of Neurology, vol. 248, no. 7, pp. 632–634, 2001. View at Publisher · View at Google Scholar · View at Scopus
  556. A. V. Nieves and A. E. Lang, “Treatment of excessive daytime sleepiness in patients with Parkinson's disease with Modafinil,” Clinical Neuropharmacology, vol. 25, no. 2, pp. 111–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  557. H. Tyne, J. Brooks, J. Taylor, S. Vinjamuri, G. Baker, and M. Steiger, “A double blind placebo controlled study of modafinil for Parkinson's disease related fatigue,” Parkinsonism & Related Disorders, vol. 13, supplement 2, pp. S113–S114, 2007. View at Publisher · View at Google Scholar
  558. H. L. Tyne, J. Taylor, G. A. Baker, and M. J. Steiger, “Modafinil for Parkinson's disease fatigue,” Journal of Neurology, vol. 257, no. 3, pp. 452–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  559. C. H. Adler, J. N. Caviness, J. G. Hentz, M. Lind, and J. Tiede, “Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease,” Movement Disorders, vol. 18, no. 3, pp. 287–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  560. B. Högl, M. Saletu, E. Brandauer et al., “Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial,” Sleep, vol. 25, no. 8, pp. 905–909, 2002. View at Google Scholar · View at Scopus
  561. J. S. Lou, D. M. Dimitrova, B. S. Park et al., “Using modafinil to treat fatigue in parkinson disease: a double-blind, placebo-controlled pilot study,” Clinical Neuropharmacology, vol. 32, no. 6, pp. 305–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  562. J. S. Lou, D. Dimitrova, S. Johnson, R. Eaton, and J. Nutt, “Modafinil reduces fatigue in PD—a double-blind, placebo-controlled pilot study,” Annals of Neurology, vol. 62, supplement 11, article S8, 2007. View at Google Scholar
  563. W. G. Ondo, R. Fayle, F. Atassi, and J. Jankovic, “Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 12, pp. 1636–1639, 2005. View at Publisher · View at Google Scholar · View at Scopus
  564. T. I. Morgenthaler, V. K. Kapur, T. Brown et al., “Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin: an American Academy of Sleep Medicine report,” Sleep, vol. 30, no. 12, pp. 1705–1711, 2007. View at Google Scholar · View at Scopus
  565. T. A. Zesiewicz, K. L. Sullivan, I. Arnulf et al., “Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards subcommittee of the American academy of neurology,” Neurology, vol. 74, no. 11, pp. 924–931, 2010. View at Publisher · View at Google Scholar · View at Scopus
  566. P. Huot and S. H. Fox, “Nondopaminergic treatments for Parkinson's disease,” Neurodegenerative Disease Management, vol. 1, no. 6, pp. 491–512, 2011. View at Publisher · View at Google Scholar
  567. NCT00393562, http://www.clinicaltrials.gov/.
  568. “Attention modulation for treatment of Parkinson's disease adn dementia with Lewy bodies (armodafinil),” NCT01256905, http://www.clinicaltrials.gov/.
  569. S. Hauber, S. Sommer, B. Valastro, G. Flik, and W. Danysz, “MRZ-9547 invigorates effortful responding in rats: implications for the treatment of fatigue in Parkinson’s disease,” Movement Disorders, vol. 29, supplement 1, p. S317, 2014. View at Google Scholar
  570. W. Danysz, F. Mela, and A. Dekundy, “MRZ-9547 shows antiParkinsonian-like activity in animal models of Parkinson's disease,” Movement Disorders, vol. 29, supplement 1, pp. S138–S139, 2014. View at Google Scholar
  571. P. Mendes, H. Dersch, and B. Katgely, “A phase I study to investigate safety, tolerability and pharmacokinetics of MRZ-9547 in healthy subjects,” Movement Disorders, vol. 29, supplement 1, p. S143, 2014. View at Google Scholar
  572. T. H. Johnston, S. H. Fox, J. Ma, L. Shao, U. Campbell, and J. M. Brotchie, “Anti-parkinsonian actions of the mixed monoamIne re-uptake inhibitors SEP-228791 and SEP-226330 in the MPTP-lesioned macaque model of Parkinson's disease [abstract],” Social Neuroscience, 2009. View at Google Scholar
  573. P. C. Contreras, M. E. Bremer, and T. S. Rao, “GBR-12909 and fluspirilene potently inhibited binding of [3H] (+)3-PPP to sigma receptors in rat brain,” Life Sciences, vol. 47, no. 22, pp. PL133–PL137, 1990. View at Google Scholar
  574. M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner, “Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates,” European Journal of Pharmacology, vol. 451, no. 2, pp. 157–160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  575. O. Rascol, C. Goetz, W. Koller, W. Poewe, and C. Sampaio, “Treatment interventions for Parkinson's disease: an evidence based assessment,” The Lancet, vol. 359, no. 9317, pp. 1589–1598, 2002. View at Publisher · View at Google Scholar · View at Scopus
  576. R. K. B. Pearce, T. Banerji, J. Scheel-Kruger, and P. Jenner, “The dopamine reuptake blocker NS 2214 increases locomotor activity but does not produce dyskinesias in MPTP-treated common marmosets,” British Journal of Pharmacology, vol. 116, supplement, p. 304P, 1995. View at Google Scholar
  577. P. Moldt, F. Watjen, and J. Scheel-Kruger, “Tropane-2-aldoxime derivatives as nevro transmitter reuptake inhibitors,” United States Patent number 5,736,556. 1998.
  578. R. K. B. Pearce, L. A. Smith, M. J. Jackson, T. Banerji, J. Scheel-Krüger, and P. Jenner, “The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets,” Movement Disorders, vol. 17, no. 5, pp. 877–886, 2002. View at Publisher · View at Google Scholar · View at Scopus
  579. E. J. Frackiewicz, S. S. Jhee, T. M. Shiovitz et al., “Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa,” The Annals of Pharmacotherapy, vol. 36, no. 2, pp. 225–230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  580. K. Archibald, “CPT 2000—seventh conference on clinical pharmacology and therapeutics and fourth congress of the European Association for Clinical Pharmacology and Therapeutics. 12–20 July 2000, Florence, Italy,” IDrugs, vol. 3, pp. 1124–1133, 2000. View at Google Scholar
  581. N. R. Cutler, D. E. Salazar, and J. J. Sramek, “Assessments of BMS-204756 (brasofensine) co-administered with levodopa/carbidopa to Parkinson's disease patients,” British Journal of Clinical Pharmacology, Abs 711, 2000. View at Google Scholar
  582. M. Zhu, D. B. Whigan, S. Y. Chang, and R. C. Dockens, “Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans,” Drug Metabolism and Disposition, vol. 36, no. 1, pp. 24–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  583. P. Yu, “Brasofensine NeuroSearch,” Current Opinion in Investigational Drugs, vol. 1, no. 4, pp. 504–507, 2000. View at Google Scholar · View at Scopus
  584. T. H. Johnston and J. M. Brotchie, “Drugs in development for Parkinson's disease: an update,” Current Opinion in Investigational Drugs, vol. 7, no. 1, pp. 25–32, 2006. View at Google Scholar · View at Scopus
  585. J. D. Fryer and R. J. Lukas, “Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine,” The Journal of Pharmacology and Experimental Therapeutics, vol. 288, no. 1, pp. 88–92, 1999. View at Google Scholar · View at Scopus
  586. B. R. Cooper, T. J. Hester, and R. A. Maxwell, “Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo,” The Journal of Pharmacology and Experimental Therapeutics, vol. 215, no. 1, pp. 127–134, 1980. View at Google Scholar · View at Scopus
  587. M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner, “The antiparkinsonian ability of bupropion in MPTP-treated common marmosets,” British Journal of Pharmacology, vol. 125, suplement, p. 66P, 1998. View at Google Scholar
  588. M. J. Hansard, M. J. Jackson, L. A. Smith, S. Rose, and P. Jenner, “A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets,” Behavioural Pharmacology, vol. 22, no. 3, pp. 269–274, 2011. View at Publisher · View at Google Scholar · View at Scopus
  589. S. Gebhardt, H. Röttgers, A. Bäcker, U. Schu, and J. C. Krieg, “Treatment of panic disorder with bupropion in a patient with Parkinson's disease,” Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 5, pp. 575–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  590. A. F. G. Leentjens, F. R. J. Verhey, and F. W. Vreeling, “A patient with Parkinson's disease suffering from depression was successfully treated with bupropion,” Nederlands Tijdschrift voor Geneeskunde, vol. 144, no. 45, pp. 2157–2159, 2000. View at Google Scholar · View at Scopus
  591. M. Załuska and A. Dyduch, “Bupropion in the treatment of depression in Parkinson's disease,” International Psychogeriatrics, vol. 23, no. 2, pp. 325–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  592. W. M. Stein and S. Read, “Chronic pain in the setting of Parkinson's disease and depression,” Journal of Pain and Symptom Management, vol. 14, no. 4, pp. 255–258, 1997. View at Publisher · View at Google Scholar · View at Scopus
  593. I. Liberzon, J. R. Dequardo, and K. R. Silk, “Bupropion and delirium,” The American Journal of Psychiatry, vol. 147, no. 12, pp. 1689–1690, 1990. View at Google Scholar · View at Scopus
  594. D. Benincasa, C. Pellicano, A. Fanciulli, and F. E. Pontieri, “Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease,” Movement Disorders, vol. 26, no. 2, pp. 355–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  595. W. C. Kim, H. S. Kim, S. H. Oh, O. J. Kim, and M. S. Lee, “Effects of bupropion on depression of Parkinson's disease: open-label 12-week trial in Korea,” Movement Disorders, vol. 24, supplement 1, article S241, 2009. View at Google Scholar
  596. C. G. Goetz, C. M. Tanner, and H. L. Klawans, “Bupropion in Parkinson's disease,” Neurology, vol. 34, no. 8, pp. 1092–1094, 1984. View at Publisher · View at Google Scholar · View at Scopus
  597. W. C. Kim, S. H. Oh, H. S. Kim, and O. J. Kim, “Bupropion on freezing of gait in Parkinson’s disease [abstract],” Movement Disorders, vol. 26, supplement 2, pp. s106–s107, 2011. View at Google Scholar
  598. Y. S. Park and W. C. Kim, “Bupropion on freezing of gait in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 18, supplement 2, p. S133, 2012. View at Google Scholar
  599. M. Carta, A. M. Allan, L. D. Partridge, and C. F. Valenzuela, “Cocaine inhibits 5-HT3 receptor function in neurons from transgenic mice overexpressing the receptor,” European Journal of Pharmacology, vol. 459, no. 2-3, pp. 167–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  600. A.-L. Brownell, D. R. Elmaleh, P. C. Meltzer et al., “Cocaine congeners as PET imaging probes for dopamine terminals,” Journal of Nuclear Medicine, vol. 37, no. 7, pp. 1186–1192, 1996. View at Google Scholar · View at Scopus
  601. J. W. Boja, E. J. Cline, F. I. Carroll et al., “High potency cocaine analogs: neurochemical, imaging, and behavioral studies,” Annals of the New York Academy of Sciences, vol. 654, pp. 282–291, 1992. View at Publisher · View at Google Scholar · View at Scopus
  602. M. J. Kaufman and B. K. Madras, “Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-disease striatum,” Synapse, vol. 9, no. 1, pp. 43–49, 1991. View at Publisher · View at Google Scholar · View at Scopus
  603. H. Schoemaker, C. Pimoule, S. Arbilla, B. Scatton, F. Javoy-Agid, and S. Z. Langer, “Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 329, no. 3, pp. 227–235, 1985. View at Publisher · View at Google Scholar · View at Scopus
  604. C. Pimoule, H. Schoemaker, F. Javoy-Agid, B. Scatton, Y. Agid, and S. Z. Langer, “Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson's disease,” European Journal of Pharmacology, vol. 95, no. 1-2, pp. 145–146, 1983. View at Publisher · View at Google Scholar · View at Scopus
  605. D. Doyle, “Adolf Hitler's medical care,” The journal of the Royal College of Physicians of Edinburgh, vol. 35, no. 1, pp. 75–82, 2005. View at Google Scholar · View at Scopus
  606. F. Gerstenbrand and E. Karamat, “Adolf Hitler's Parkinson's disease and an attempt to analyse his personality structure,” European Journal of Neurology, vol. 6, no. 2, pp. 121–127, 1999. View at Publisher · View at Google Scholar · View at Scopus
  607. E. Gibbels, “Hitler's neurologic disease—differential diagnosis of Parkinson syndrome,” Fortschritte der Neurologie Psychiatrie, vol. 57, no. 12, pp. 505–517, 1989. View at Publisher · View at Google Scholar · View at Scopus
  608. E. Gibbels, “Hitler's Parkinson syndrome. A posthumous motility analysis of film records of the German weekly news 1940–1945,” Nervenarzt, vol. 59, no. 9, pp. 521–528, 1988. View at Google Scholar
  609. P. J. Garcia Ruiz, “Did Hitler's parkinsonism influence in the development of World War II?” Neurologia, vol. 15, no. 2, pp. 87–88, 2000. View at Google Scholar · View at Scopus
  610. F. Redlich, “Hitler's diagnosis,” The Journal of Nervous and Mental Disease, vol. 188, no. 5, pp. 311–314, 2000. View at Google Scholar
  611. M. Biddiss, “Disease and dictatorship: the case of Hitler's Reich,” Journal of the Royal Society of Medicine, vol. 90, no. 6, pp. 342–346, 1997. View at Google Scholar · View at Scopus
  612. A. Lieberman, “Hitler's Parkinson's disease began in 1933,” Movement Disorders, vol. 12, no. 2, pp. 239–240, 1997. View at Publisher · View at Google Scholar · View at Scopus
  613. J. V. Hägglund, “Hitler's parkinson's disease: a videotape illustration,” Movement Disorders, vol. 7, no. 4, pp. 383–384, 1992. View at Publisher · View at Google Scholar · View at Scopus
  614. E. H. Friedman, “More on Hitler and Parkinson's disease,” The New England Journal of Medicine, vol. 316, no. 2, article 114, 1987. View at Google Scholar · View at Scopus
  615. A. Lieberman, “Adolf Hitler's cognitive disorder and how it affected his conduct of World War II,” Advances in Neurology, vol. 80, pp. 459–466, 1999. View at Google Scholar · View at Scopus
  616. Á. L. Guerrero Peral, “Parkinson's disease of Adolf Hitler and its influence in the development of World War Second,” Neurologia, vol. 18, no. 2, pp. 66–69, 2003. View at Google Scholar · View at Scopus
  617. A. Di Rocco, S. Nasser, and P. Werner, “Inhaled cocaine used to relieve ‘off’ periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases,” Journal of Clinical Psychopharmacology, vol. 26, no. 6, pp. 689–690, 2006. View at Publisher · View at Google Scholar · View at Scopus
  618. P. Domingo and E. Martinez, “Parkinsonism associated with long-term cocaine abuse,” Archives of Internal Medicine, vol. 157, no. 2, p. 241, 1997. View at Publisher · View at Google Scholar · View at Scopus
  619. H. Sawada, K. Yamakawa, H. Yamakado et al., “Cocaine and phenylephrine eye drop test for Parkinson disease,” Journal of the American Medical Association, vol. 293, no. 8, pp. 932–934, 2005. View at Google Scholar · View at Scopus
  620. P. W. Carmel, “Sympathetic deficits following thalamotomy,” Archives of Neurology, vol. 18, no. 4, pp. 378–387, 1968. View at Publisher · View at Google Scholar · View at Scopus
  621. M. I. Weintraub, D. Gaasterland, and M. van Woert, “L-dopa-induced anisocoria in latent Horner's syndrome,” Neurology, vol. 20, no. 4, p. 417, 1970. View at Google Scholar · View at Scopus
  622. M. I. Weintraub, D. Gaasterland, and M. H. van Woert, “Pupillary effects of levodopa therapy—development of anisocoria in latent Horner's syndrome,” The New England Journal of Medicine, vol. 283, no. 3, pp. 120–123, 1970. View at Publisher · View at Google Scholar · View at Scopus
  623. T. Kano, Y. Suzuki, M. Shibuya, K. Kiuchi, and M. Hagiwara, “Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice,” NeuroReport, vol. 6, no. 16, pp. 2197–2200, 1995. View at Publisher · View at Google Scholar · View at Scopus
  624. P. B. Silverman, “On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat,” European Journal of Pharmacology, vol. 242, no. 1, pp. 31–36, 1993. View at Publisher · View at Google Scholar · View at Scopus
  625. S. A. Lloyd, C. J. Faherty, and R. J. Smeyne, “Adult and in utero exposure to cocaine alters sensitivity to the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Neuroscience, vol. 137, no. 3, pp. 905–913, 2006. View at Publisher · View at Google Scholar · View at Scopus
  626. V. Dhopesh, A. Macfadden, I. Maany, and G. Gamble, “Absence of Parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine,” Psychiatric Services, vol. 48, no. 1, pp. 95–97, 1997. View at Publisher · View at Google Scholar · View at Scopus
  627. V. P. Dhopesh, P. M. Yagnik, and W. W. Weddington, “Can cocaine abuse cause Parkinsonism?” The American Journal on Addictions, vol. 6, no. 2, pp. 177–179, 1997. View at Publisher · View at Google Scholar · View at Scopus
  628. Y. Zengin-Toktas, N. Authier, H. Denizot et al., “Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat,” Neuropharmacology, vol. 70, pp. 74–82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  629. J. H. Friedman and V. Chang, “Crack cocaine use due to dopamine agonist therapy in Parkinson disease,” Neurology, vol. 80, no. 24, pp. 2269–2270, 2013. View at Publisher · View at Google Scholar
  630. J. S. Markowitz, C. L. DeVane, L. K. Pestreich, K. S. Patrick, and R. Muniz, “A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study,” Journal of Child and Adolescent Psychopharmacology, vol. 16, no. 6, pp. 687–698, 2006. View at Publisher · View at Google Scholar · View at Scopus
  631. E. Auriel, J. M. Hausdorff, and N. Giladi, “Methylphenidate for the treatment of Parkinson disease and other neurological disorders,” Clinical Neuropharmacology, vol. 32, no. 2, pp. 75–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  632. J. O. Aasly, M. Shi, V. Sossi et al., “Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers,” Neurology, vol. 78, no. 1, pp. 55–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  633. R. Nandhagopal, L. Kuramoto, M. Schulzer et al., “Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease,” Brain, vol. 134, no. 11, pp. 3290–3298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  634. M. Shi, A. R. Furay, V. Sossi et al., “DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function,” Neurobiology of Aging, vol. 33, no. 4, pp. 836.e5–836.e7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  635. K. Fischer, V. Sossi, A. Von Ameln-Mayerhofer, G. Reischl, and B. J. Pichler, “In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET,” NeuroImage, vol. 59, no. 3, pp. 2413–2422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  636. V. Sossi, K. Dinelle, S. Jivan, K. Fischer, J. E. Holden, and D. Doudet, “In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of parkinson disease using 11C-methylphenidate PET,” Journal of Nuclear Medicine, vol. 53, no. 5, pp. 813–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  637. K. M. Koochesfahani, R. de la Fuente-Fernández, V. Sossi et al., “Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies,” Movement Disorders, vol. 21, no. 7, pp. 970–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  638. S. Thobois, C. Ardouin, E. Lhommée et al., “Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation,” Brain, vol. 133, no. 4, pp. 1111–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  639. S. M. Fleming, Y. Delville, and T. Schallert, “An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate,” Behavioural Brain Research, vol. 156, no. 2, pp. 201–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  640. P. Chopin, F. C. Colpaert, and M. Marien, “Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 288, no. 2, pp. 798–804, 1999. View at Google Scholar · View at Scopus
  641. J. S. Schneider, Z.-Q. Sun, and D. P. Roeltgen, “Effects of dopamine agonists on delayed response performance in chronic low-dosing MPTP-treated monkeys,” Pharmacology Biochemistry and Behavior, vol. 48, no. 1, pp. 235–240, 1994. View at Publisher · View at Google Scholar · View at Scopus
  642. A. Chatterjee and S. Fahn, “Methylphenidate treats apathy in Parkinson's disease,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 14, no. 4, pp. 461–462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  643. E. Auriel, J. M. Hausdorff, T. Herman, E. S. Simon, and N. Giladi, “Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study,” Clinical Neuropharmacology, vol. 29, no. 1, pp. 15–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  644. G. Cheng and J. F. Morley, “Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate,” Clinical Nuclear Medicine, vol. 39, pp. 211–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  645. A. H. Evans, A. D. Lawrence, and A. J. Lees, “Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 3, pp. 267–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  646. D. A. Mendonça, K. Menezes, and M. S. Jog, “Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial,” Movement Disorders, vol. 22, no. 14, pp. 2070–2076, 2007. View at Publisher · View at Google Scholar · View at Scopus
  647. J. M. Alisky, “A new approach to Parkinson's disease combining caffeine, methylphenidate, and anticholinergic agents: case histories, pharmacological data, and a conceptual framework from traditional Chinese medicine,” Hong Kong Medical Journal, vol. 12, no. 2, p. 168, 2006. View at Google Scholar · View at Scopus
  648. A. M. Persico, S. Reich, J. E. Henningfield, M. J. Kuhar, and G. R. Uhl, “Parkinsonian patients report blunted subjective effects of methylphenidate,” Experimental and Clinical Psychopharmacology, vol. 6, no. 1, pp. 54–63, 1998. View at Publisher · View at Google Scholar · View at Scopus
  649. R. L. Drijgers, F. R. J. Verhey, G. Tissingh, P. H. M. F. van Domburg, P. Aalten, and A. F. G. Leentjens, “The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate,” Journal of the Neurological Sciences, vol. 320, no. 1-2, pp. 121–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  650. R. Cantello, M. Aguggia, M. Gilli et al., “Analgesic action of methylphenidate on parkinsonian sensory symptoms: mechanisms and pathophysiological implications,” Archives of Neurology, vol. 45, no. 9, pp. 973–976, 1988. View at Publisher · View at Google Scholar · View at Scopus
  651. R. Cantello, M. Aguggia, M. Gilli et al., “Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the ‘hedonic’ dopamine synapse,” Journal of Neurology Neurosurgery & Psychiatry, vol. 52, no. 6, pp. 724–731, 1989. View at Publisher · View at Google Scholar · View at Scopus
  652. L. Pollak, Y. Dobronevsky, T. Prohorov, S. Bahunker, and J. M. Rabey, “Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state,” Journal of Neural Transmission, Supplementa, no. 72, pp. 145–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  653. L. Pollak, E. Dovbronevsky, T. Prokhorov, S. Bhonkar, and J. M. Rabey, “Low dose methylphenidate improves freezing in advanced Parkinson's disease during the off-state,” Movement Disorders, vol. 23, supplement 1, pp. S85–S86, 2008. View at Google Scholar
  654. L. Pollak, Y. Dobronevsky, T. Prohorov, S. Bahunker, and J. M. Rabey, “Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state,” Journal of Neural Transmission, vol. 22, supplement 16, pp. 145–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  655. A. J. Espay, A. Kumar Dwivedi, S. Savage et al., “Methylphenidate for the treatment of gait impairment in Parkinson's disease: a randomized, double-blind, placebo-controlled cross-over trial,” Movement Disorders, vol. 25, supplement 2, p. S296, 2010. View at Google Scholar
  656. A. J. Espay, A. K. Dwivedi, M. Payne et al., “Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial,” Neurology, vol. 76, no. 14, pp. 1256–1262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  657. A. M. Halliday and P. W. Nathan, “Methyl phenidate in parkinsonism,” British Medical Journal, vol. 1, no. 5240, pp. 1652–1655, 1961. View at Publisher · View at Google Scholar · View at Scopus
  658. F. Giberti, G. Gianniotti, and S. Spizzirri, “Further results of new therapy of Parkinsonian syndromes; therapeutic action of 3-phenyl-3-b-diethylamino-ethyl-2-6-dioxy-piperidine hydrochloride administered alone and with reserpine and ritalin,” Gazzetta Medica Italiana, vol. 116, no. 9, pp. 404–407, 1957. View at Google Scholar · View at Scopus
  659. L. I. Lapinsohn, “Ritalin and serpasil in the treatment of Parkinson's disease,” Diseases of the Nervous System, vol. 17, no. 11, pp. 363–364, 1956. View at Google Scholar · View at Scopus
  660. R. Camicioli, E. Lea, J. G. Nutt, G. Sexton, and B. S. Oken, “Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: a pilot study,” Clinical Neuropharmacology, vol. 24, no. 4, pp. 208–213, 2001. View at Publisher · View at Google Scholar · View at Scopus
  661. J. G. Nutt, J. H. Carter, and G. J. Sexton, “The dopamine transporter: importance in Parkinson's disease,” Annals of Neurology, vol. 55, no. 6, pp. 766–773, 2004. View at Publisher · View at Google Scholar · View at Scopus
  662. J. G. Nutt, J. H. Carter, and N. E. Carlson, “Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial,” Archives of Neurology, vol. 64, no. 3, pp. 319–323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  663. D. Devos, P. Krystkowiak, F. Clement et al., “Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 5, pp. 470–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  664. C. Moreau, A. Delval, K. Dujardin et al., “Methylphenidate for gait and attention disorders in advanced parkinsonian patients with subthalamic stimulation: a multicentric randomized, double-blind, placebo-controlled study,” Neurology, vol. 78, supplement 1, Article ID S02.004, 2012. View at Publisher · View at Google Scholar
  665. C. Moreau, A. Delval, L. Defebvre et al., “Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial,” The Lancet Neurology, vol. 11, no. 7, pp. 589–596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  666. D. Devos and Parkgait Study Group, “Methylphenidate for freezing of gait and attention deficit in parkinsonian patients under subthalamic stimulation (PARKGAIT-II): a randomised placebo-controlled trial,” Movement Disorders, vol. 27, supplement 1, pp. S113–S114, 2012. View at Google Scholar
  667. NCT01244269, http://www.clinicaltrials.gov/.
  668. B. Costall, D. M. Kelly, and R. J. Naylor, “Nomifensine: a potent dopaminergic agonist of antiparkinson potential,” Psychopharmacologia, vol. 41, no. 2, pp. 153–164, 1975. View at Publisher · View at Google Scholar · View at Scopus
  669. E. T. McKinley, T. C. Baranowski, D. O. Blavo, C. Cato, T. N. Doan, and A. L. Rubinstein, “Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons,” Molecular Brain Research, vol. 141, no. 2, pp. 128–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  670. W. Schultz, E. Scarnati, E. Sundström, T. Tsutsumi, and G. Jonsson, “The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys,” Experimental Brain Research, vol. 63, no. 1, pp. 216–220, 1986. View at Publisher · View at Google Scholar · View at Scopus
  671. W. Schultz, E. Scarnati, E. Sundström, and R. Romo, “Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions,” Neuroscience, vol. 31, no. 1, pp. 219–230, 1989. View at Publisher · View at Google Scholar · View at Scopus
  672. C. C. Huang and E. H. Y. Lee, “Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats,” Journal of Neuroscience Research, vol. 41, no. 4, pp. 471–480, 1995. View at Publisher · View at Google Scholar · View at Scopus
  673. F. Rode, G. Munro, D. Holst et al., “Positive allosteric modulation of α4β2 nAChR agonist induced behaviour,” Brain Research, vol. 1458, pp. 67–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  674. S. Sarre, N. De Klippel, P. Herregodts, G. Ebinger, and Y. Michotte, “Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-Parkinsonian rat studied with microdialysis,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 350, no. 1, pp. 15–21, 1994. View at Publisher · View at Google Scholar · View at Scopus
  675. P. Brundin, R. E. Strecker, H. Widner et al., “Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release,” Experimental Brain Research, vol. 70, no. 1, pp. 192–208, 1988. View at Google Scholar · View at Scopus
  676. M. Lundblad, M. Decressac, B. Mattsson, and A. Björklund, “Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3213–3219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  677. G. Oyama, K. Yoshimi, S. Natori et al., “Impaired in vivo dopamine release in parkin knockout mice,” Brain Research, vol. 1352, pp. 214–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  678. Y. Li, W. Liu, T. F. Oo et al., “Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease,” Nature Neuroscience, vol. 12, no. 7, pp. 826–828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  679. R.-M. Marié, L. Barre, P. Rioux, P. Allain, B. Lechevalier, and J.-C. Baron, “PET imaging of neocortical monoaminergic terminals in Parkinson's disease,” Journal of Neural Transmission: Parkinson's Disease and Dementia Section, vol. 9, no. 1, pp. 55–71, 1995. View at Publisher · View at Google Scholar · View at Scopus
  680. C. Sioka, A. Fotopoulos, and A. P. Kyritsis, “Recent advances in PET imaging for evaluation of Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 8, pp. 1594–1603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  681. J. Tedroff, S.-M. Aquilonius, P. Hartvig, E. Bredberg, P. Bjurling, and B. Langstrom, “Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response,” Acta Neurologica Scandinavica, vol. 85, no. 2, pp. 95–102, 1992. View at Publisher · View at Google Scholar · View at Scopus
  682. K. L. Leenders, E. P. Salmon, P. Tyrrell et al., “The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease,” Archives of Neurology, vol. 47, no. 12, pp. 1290–1298, 1990. View at Publisher · View at Google Scholar · View at Scopus
  683. R. M. Marié, L. Barré, B. Dupuy, F. Viader, G. Defer, and J. C. Baron, “Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease,” Neuroscience Letters, vol. 260, no. 2, pp. 77–80, 1999. View at Publisher · View at Google Scholar · View at Scopus
  684. S. P. Close, P. J. Elliott, A. G. Hayes, and A. S. Marriott, “Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease,” Psychopharmacology, vol. 102, no. 3, pp. 295–300, 1990. View at Publisher · View at Google Scholar · View at Scopus
  685. A. Agnoli, M. Baldassarre, S. Ruggieri, P. Falaschi, R. D. Urso, and A. Rocco, “Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response,” Journal of Neural Transmission—General Section, vol. 51, no. 1-2, pp. 123–134, 1981. View at Publisher · View at Google Scholar · View at Scopus
  686. A. Agnoli, S. Ruggieri, M. Baldassarre et al., “Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study,” Progress in Clinical and Biological Research, vol. 39, pp. 215–224, 1980. View at Google Scholar · View at Scopus
  687. R. Sandyk, “Nomifensine in advanced parkinsonism,” Clinical Neuropharmacology, vol. 8, no. 3, pp. 296–297, 1985. View at Publisher · View at Google Scholar · View at Scopus
  688. D. M. Park, L. J. Findley, and P. F. Teychenne, “Nomifensine in parkinsonism,” British Journal of Clinical Pharmacology, vol. 4, supplement 2, pp. 185S–186S, 1977. View at Google Scholar · View at Scopus
  689. D. M. Park, L. J. Findley, G. Hanks, and M. Sandler, “Nomifensine: effect in parkinsonian patients not receiving levodopa,” Journal of Neurology Neurosurgery and Psychiatry, vol. 44, no. 4, pp. 352–354, 1981. View at Publisher · View at Google Scholar · View at Scopus
  690. P. Bedard, J. D. Parkes, and C. D. Marsden, “Nomifensine in Parkinson's disease,” British Journal of Clinical Pharmacology, vol. 4, supplement 2, pp. 187S–190S, 1977. View at Google Scholar · View at Scopus
  691. P. F. Teychenne, D. M. Park, L. J. Findley, F. C. Rose, and D. B. Calne, “Nomifensine in Parkinsonism,” Journal of Neurology Neurosurgery and Psychiatry, vol. 39, no. 12, pp. 1219–1221, 1976. View at Publisher · View at Google Scholar · View at Scopus
  692. T. H. Johnston, Z. Millar, P. Huot et al., “A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates,” The FASEB Journal, vol. 26, no. 5, pp. 2154–2163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  693. D. Salomoncyzk, M. McIldowie, J. M. Brotchie, M. Piggott, and J. E. Nash, “Characterization of the neurotoxicity of MDMA analogues in a cell culture model of Parkinson's disease: implications for symptomatic therapies,” Movement Disorders, vol. 21, supplement 15, article S639, 2006. View at Google Scholar
  694. M. J. Piggott, T. H. Johnston, M. J. McIldowie et al., “UWA-0101 extends the duration and quality of antiparkinsonian benefit provided by L-DOPA in the MPTP-lesioned primate model of Parkinson's disease,” Society for Neuroscience, 2007.
  695. M. J. Piggott, K. Wagg, T. H. Johnston, J. Lee, J. Gomez-Ramirez, and J. M. Brotchie, “ATK-0091, and related alpha-substituted analogues of MDMA (‘Ecstasy’), may have potential in the treatment of Parkinson's disease,” Movement Disorders, vol. 19, supplement 9, p. s265, 2004. View at Google Scholar
  696. T. H. Johnston, S. H. Fox, M. J. McIldowie, M. J. Piggott, and J. M. Brotchie, “An alpha-substituted MDMA (‘ecstasy’) analogue, ATK-0101, extends the duration of L-DOPA action in the MPTP-lesioned primate model of Parkinson's disease,” Movement Disorders, vol. 21, supplement 15, p. S642, 2006, [Abstract]. View at Google Scholar
  697. P. Huot, T. H. Johnston, K. D. Lewis et al., “Mixed dopamine (DAT) and serotonin (SERT) re-uptake inhibitors with equal DAT: SERT affinity increase quality and duration of anti-parkinsonian action of L-DOPA in the MPTP-lesioned primate,” Movement Disorders, vol. 26, supplement 2, p. S281, 2011. View at Google Scholar
  698. P. Huot, T. H. Johnston, M. N. Gandy et al., “The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset,” PLoS ONE, vol. 7, no. 9, Article ID e45587, 2012. View at Publisher · View at Google Scholar · View at Scopus
  699. P. Huot, T. H. Johnston, K. D. Lewis et al., “UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset,” Neuropharmacology, vol. 82, pp. 76–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  700. J. M. Brotchie, T. H. Johnston, S. H. Fox, K. Lewis, and M. J. Piggott, “UWA-0121: a novel L-DOPA dopaminergic/ serotonergic agent with ability to extend L-DOPA action in the MPTP-lesioned primate model of Parkinson's disease,” Society for Neuroscience, 2008.
  701. R. Arai, N. Karasawa, and I. Nagatsu, “Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study,” Brain Research, vol. 706, no. 1, pp. 177–179, 1996. View at Publisher · View at Google Scholar · View at Scopus
  702. F. Tison, N. Mons, M. Geffard, and P. Henry, “The metabolism of exogenous L-Dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain,” Journal of Neural Transmission: Parkinson's Disease and Dementia Section, vol. 3, no. 1, pp. 27–39, 1991. View at Publisher · View at Google Scholar · View at Scopus
  703. O. S. Gershanik, R. E. Heikkila, and R. C. Duvoisin, “The role of serotonin in the action of L-dopa in an animal model of parkinsonism,” Neurology, vol. 29, supplement, article S553, 1978. View at Google Scholar
  704. P. Huot, S. H. Fox, and J. M. Brotchie, “The serotonergic system in Parkinson's disease,” Progress in Neurobiology, vol. 95, no. 2, pp. 163–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  705. D. W. Miller and E. D. Abercrombie, “Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats,” Journal of Neurochemistry, vol. 72, no. 4, pp. 1516–1522, 1999. View at Publisher · View at Google Scholar · View at Scopus
  706. P. Huot, T. H. Johnston, L. Winkelmolen, S. H. Fox, and J. M. Brotchie, “5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA,” Neurobiology of Aging, vol. 33, no. 1, pp. 194.e5–194.e15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  707. P. Jenner, N. M. J. Rupniak, S. Rose et al., “1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset,” Neuroscience Letters, vol. 50, no. 1–3, pp. 85–90, 1984. View at Publisher · View at Google Scholar · View at Scopus
  708. E. L. Lane, S. C. Cheetham, and P. Jenner, “Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours,” European Journal of Neuroscience, vol. 21, no. 1, pp. 179–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  709. M. A. Cenci, A. Tranberg, M. Andersson, and A. Hilbertson, “Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment,” Neuroscience, vol. 94, no. 2, pp. 515–527, 1999. View at Publisher · View at Google Scholar · View at Scopus
  710. P. Huot, T. H. Johnston, J. B. Koprich, S. H. Fox, and J. M. Brotchie, “The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease,” Pharmacological Reviews, vol. 65, no. 1, pp. 171–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  711. E. L. Lane, S. Cheetham, and P. Jenner, “Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398,” Journal of Neural Transmission, vol. 115, no. 3, pp. 423–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  712. E. L. Lane, S. C. Cheetham, and P. Jenner, “Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?” Experimental Neurology, vol. 197, no. 2, pp. 284–290, 2006. View at Publisher · View at Google Scholar · View at Scopus
  713. M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner, “The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates,” Movement Disorders, vol. 19, no. 1, pp. 15–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  714. L. A. Smith, S. Cheetham, E. Maratos, D. J. Heal, P. Jenner, and C. D. Marsden, “BTS 74 398 reverses motor deficits in MPTP-treated common marmosets without inducing dyskinesias,” British Journal of Pharmacology, vol. 123, supplement, pp. 123–253P, 1998. View at Google Scholar
  715. A. E. Fleckenstein, T. J. Volz, E. L. Riddle, J. W. Gibb, and G. R. Hanson, “New insights into the mechanism of action of amphetamines,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 681–698, 2007. View at Publisher · View at Google Scholar · View at Scopus
  716. V. Setola, S. J. Hufeisen, K. J. Grande-Allen et al., “3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro,” Molecular Pharmacology, vol. 63, no. 6, pp. 1223–1229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  717. R. A. Lyon, R. A. Glennon, and M. Titeler, “3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors,” Psychopharmacology, vol. 88, no. 4, pp. 525–526, 1986. View at Publisher · View at Google Scholar · View at Scopus
  718. E. T. K. Leonardi and E. C. Azmitia, “MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac),” Neuropsychopharmacology, vol. 10, no. 4, pp. 231–238, 1994. View at Publisher · View at Google Scholar · View at Scopus
  719. J. F. Nash, B. L. Roth, J. D. Brodkin, D. E. Nichols, and G. A. Gudelsky, “Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors,” Neuroscience Letters, vol. 177, no. 1-2, pp. 111–115, 1994. View at Publisher · View at Google Scholar · View at Scopus
  720. P. Huot, T. H. Johnston, K. D. Lewis et al., “Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time,” Journal of Neuroscience, vol. 31, no. 19, pp. 7190–7198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  721. G. A. Ricaurte, L. S. Forno, M. A. Wilson et al., “(±)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates,” The Journal of the American Medical Association, vol. 260, no. 1, pp. 51–55, 1988. View at Publisher · View at Google Scholar · View at Scopus
  722. M. A. Wilson, G. A. Ricaurte, and M. E. Molliver, “Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine,” Neuroscience, vol. 28, no. 1, pp. 121–137, 1989. View at Publisher · View at Google Scholar · View at Scopus
  723. E. O'Hearn, G. Battaglia, E. B. De Souza, M. J. Kuhar, and M. E. Molliver, “Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity,” Journal of Neuroscience, vol. 8, no. 8, pp. 2788–2803, 1988. View at Google Scholar · View at Scopus
  724. G. Costa, L. Frau, J. Wardas, A. Pinna, A. Plumitallo, and M. Morelli, “MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice,” Movement Disorders, vol. 28, no. 14, pp. 1957–1965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  725. S. Mintzer, S. Hickenbottom, and S. Gilman, “Parkinsonism after taking ecstasy,” The New England Journal of Medicine, vol. 340, no. 18, p. 1443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  726. R. A. Sewell and N. V. Cozzi, “More about Parkinsonism after taking ecstasy,” The New England Journal of Medicine, vol. 341, no. 18, pp. 1400–1401, 1999. View at Publisher · View at Google Scholar · View at Scopus
  727. G. J. Borg, R. A. Sewell, N. V. Cozzi et al., “More about Parkinsonism after taking ecstasy,” The New England Journal of Medicine, vol. 341, no. 18, pp. 1400–1401, 1999. View at Publisher · View at Google Scholar · View at Scopus
  728. G. A. Ricaurte, J. Yuan, G. Hatzidimitriou, B. J. Cord, and U. D. McCann, “Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (‘ecstasy’),” Science, vol. 297, no. 5590, pp. 2260–2263, 2002. View at Publisher · View at Google Scholar
  729. G. A. Ricaurte, J. Yuan, G. Hatzidimitriou, B. J. Cord, and U. D. McCann, “Retraction,” Science, vol. 301, no. 5639, p. 1479, 2003. View at Google Scholar · View at Scopus
  730. S. M. Kuniyoshi and J. Jankovic, “MDMA and parkinsonism,” The New England Journal of Medicine, vol. 349, no. 1, pp. 96–97, 2003. View at Publisher · View at Google Scholar · View at Scopus
  731. P. O'Suilleabhain and C. Giller, “Rapidly progressive parkinsonism in a self-reported user of Ecstasy and other drugs,” Movement Disorders, vol. 18, no. 11, pp. 1378–1381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  732. Y. F. Tai, R. Hoshi, C. M. Brignell et al., “Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA (‘Ecstasy’): an 18F-dopa PET Study,” Neuropsychopharmacology, vol. 36, no. 4, pp. 735–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  733. S. J. Kish, “What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?” Movement Disorders, vol. 18, no. 11, pp. 1219–1223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  734. L. Jerome, R. Doblin, and M. Mithoefer, “Ecstasy use—Parkinson's disease link tenuous,” Movement Disorders, vol. 19, no. 11, p. 1386, 2004. View at Publisher · View at Google Scholar · View at Scopus
  735. BBC, 2001, http://www.bbc.co.uk/science/horizon/2000/ecstasyagony.shtml.
  736. W. J. Schmidt, A. Mayerhofer, A. Meyer, and K.-A. Kovar, “Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?” Neuroscience Letters, vol. 330, no. 3, pp. 251–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  737. A. von Ameln-Mayerhofer, M. Hupkes, C. Riegel, F. Kluge, S. Seeger-Armbruster, and N. Y. Lettfuss, “The antiparkinsonian effects of 3,4-methylenedioxymethamphetamine in rats: role of 5-HT1A-receptors, serotonin transporter and neurochemical effects,” Behavioural Pharmacology, vol. 20, no. 1, article S107, 2009. View at Google Scholar
  738. H. B. Lebsanft, T. Kohles, K.-A. Kovar, and W. J. Schmidt, “3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy,” Synapse, vol. 55, no. 3, pp. 148–155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  739. H. B. Lebsanft, K.-A. Kovar, and W. J. Schmidt, “3,4-Methylenedioxymethamphetamine and naloxone in rat rotational behaviour and open field,” European Journal of Pharmacology, vol. 516, no. 1, pp. 34–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  740. H. B. Lebsanft, A. Mayerhofer, K.-A. Kovar, and W. J. Schmidt, “Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?” Journal of Neural Transmission, vol. 110, no. 7, pp. 707–718, 2003. View at Google Scholar · View at Scopus
  741. N. Y. Lettfuss, K. Fischer, V. Sossi, B. J. Pichler, and A. von Ameln-Mayerhofer, “Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA,” NeuroImage, vol. 63, no. 1, pp. 423–433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  742. Y. Takamatsu, H. Shiotsuki, S. Kasai et al., “Enhanced hyperthermia induced by MDMA in parkin knockout mice,” Current Neuropharmacology, vol. 9, no. 1, pp. 96–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  743. M. M. Iravani, M. J. Jackson, M. Kuoppamäki, L. A. Smith, and P. Jenner, “3,4-methylenedioxymethamphetamine (Ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates,” The Journal of Neuroscience, vol. 23, no. 27, pp. 9107–9115, 2003. View at Google Scholar · View at Scopus
  744. P. Huot, T. H. Johnston, K. D. Lewis et al., “The 5-HT2A partial agonist R-MDMA reduces psychosis-like behaviour in the MPTP-lesioned non-human primate model of Parkinson's disease,” Movement Disorders, vol. 26, supplement 2, p. S281, 2011. View at Google Scholar
  745. M. Beaudoin-Gobert, E. Metereau, J. Epinat, L. Tremblay, and V. Sgambato-Faure, “Ecstasy abolishes L-DOPA-induced dyskinesia and behavioral hyperactivity in MPTP-intoxicated monkeys,” Movement Disorders, vol. 29, supplement 1, p. S304, 2014. View at Google Scholar
  746. S. K. Hemrick-Luecke, H. D. Snoddy, and R. W. Fuller, “Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo,” Life Sciences, vol. 55, no. 7, pp. 479–483, 1994. View at Publisher · View at Google Scholar · View at Scopus
  747. A. Avila, X. Cardona, M. Martin-Baranera, P. Maho, F. Sastre, and J. Bello, “Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial,” Journal of Clinical Psychopharmacology, vol. 23, no. 5, pp. 509–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  748. F. Benazzi, “Parkinson's disease worsened by nefazodone,” International Journal of Geriatric Psychiatry, vol. 12, no. 12, p. 1195, 1997. View at Publisher · View at Google Scholar
  749. U. Thatte, “NS-2330 NeuroSearch,” Current Opinion in Investigational Drugs, vol. 2, no. 11, pp. 1592–1594, 2001. View at Google Scholar · View at Scopus
  750. R. A. Hauser, L. Salin, N. Juhel et al., “Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease,” Movement Disorders, vol. 22, no. 3, pp. 359–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  751. W. Bara-Jimenez, T. Dimitrova, A. Sherzai, A. Favit, M. M. Mouradian, and T. N. Chase, “Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease,” Movement Disorders, vol. 19, no. 10, pp. 1183–1186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  752. O. Rascol, W. Poewe, A. Lees et al., “Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced parkinson disease and motor fluctuations: the ADVANS study,” Archives of Neurology, vol. 65, no. 5, pp. 577–583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  753. A. Astrup, D. H. Meier, B. O. Mikkelsen, J. S. Villumsen, and T. M. Larsen, “Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease,” Obesity, vol. 16, no. 6, pp. 1363–1369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  754. H. R. Smith, T. J. R. Beveridge, and L. J. Porrino, “Distribution of norepinephrine transporters in the non-human primate brain,” Neuroscience, vol. 138, no. 2, pp. 703–714, 2006. View at Publisher · View at Google Scholar · View at Scopus
  755. C. M. Fattaccini, F. Bolanos-Jimenez, H. Gozlan, and M. Hamon, “Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain,” Neuropharmacology, vol. 29, no. 1, pp. 1–8, 1990. View at Publisher · View at Google Scholar · View at Scopus
  756. T. Mennini, E. Mocaer, and S. Garattini, “Tianeptine, a selective enhancer of serotonin uptake in rat brain,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 336, no. 5, pp. 478–482, 1987. View at Google Scholar · View at Scopus
  757. G. Sacchetti, I. Bonini, G. Cools Waeterloos, and R. Samanin, “Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex,” European Journal of Pharmacology, vol. 236, no. 2, pp. 171–175, 1993. View at Publisher · View at Google Scholar · View at Scopus
  758. B. Bobula and G. Hess, “Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex,” Pharmacological Reports, vol. 60, no. 6, pp. 865–871, 2008. View at Google Scholar · View at Scopus
  759. P. Svenningsson, H. Bateup, H. Qi et al., “Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine,” European Journal of Neuroscience, vol. 26, no. 12, pp. 3509–3517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  760. B. S. McEwen and J. P. Olié, “Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine,” Molecular Psychiatry, vol. 10, no. 6, pp. 525–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  761. B. S. McEwen and S. Chattarji, “Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine,” European Neuropsychopharmacology, vol. 14, supplement 5, pp. S497–S502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  762. M. H. P. Kole, L. Swan, and E. Fuchs, “The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats,” European Journal of Neuroscience, vol. 16, no. 5, pp. 807–816, 2002. View at Publisher · View at Google Scholar · View at Scopus
  763. H. Qi, F. Mailliet, M. Spedding et al., “Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation,” Neuropharmacology, vol. 56, no. 1, pp. 37–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  764. O. S. Levin, “Coaxil (tianeptine) in the treatment of depression in Parkinson's disease,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 106, no. 3, pp. 20–25, 2006. View at Google Scholar · View at Scopus
  765. O. S. Levin, “Coaxil (tianeptine) in the treatment of depression in Parkinson's disease,” Neuroscience and Behavioral Physiology, vol. 37, no. 4, pp. 419–424, 2007. View at Publisher · View at Google Scholar · View at Scopus